Skip to main content
Erschienen in: Endocrine 2/2013

01.04.2013 | Review

Cachexia in chronic heart failure: endocrine determinants and treatment perspectives

verfasst von: Norman Mangner, Yae Matsuo, Gerhard Schuler, Volker Adams

Erschienen in: Endocrine | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

It is well documented in the current literature that chronic heart failure is often associated with cachexia, defined as involuntary weight loss of 5 % in 12 month or less. Clinical studies unraveled that the presence of cachexia decreases significantly mean survival of the patient. At the molecular level mainly myofibrillar proteins are degraded, although a reduced protein synthesis may also contribute to the loss of muscle mass. Endocrine factors clearly regulate muscle mass and function by influencing the normally precisely controlled balance between protein breakdown and protein synthesis The aim of the present article is to review the knowledge in the field with respect to the role of endocrine factors for the regulation of cachexia in patients with CHF and deduce treatment perspectives.
Literatur
1.
Zurück zum Zitat W.J. Evans, J.E. Morley, J. Argiles, C. Bales, V. Baracos, D. Guttridge, A. Jatoi, K. Kalantar-Zadeh, H. Lochs, G. Mantovani, D. Marks, W.E. Mitch, M. Muscaritoli, A. Najand, P. Ponikowski, F. Rossi Fanelli, M. Schambelan, A. Schols, M. Schuster, D. Thomas, R. Wolfe, S.D. Anker, Cachexia: a new definition. Clin. Nutr. 27, 793–799 (2008)PubMedCrossRef W.J. Evans, J.E. Morley, J. Argiles, C. Bales, V. Baracos, D. Guttridge, A. Jatoi, K. Kalantar-Zadeh, H. Lochs, G. Mantovani, D. Marks, W.E. Mitch, M. Muscaritoli, A. Najand, P. Ponikowski, F. Rossi Fanelli, M. Schambelan, A. Schols, M. Schuster, D. Thomas, R. Wolfe, S.D. Anker, Cachexia: a new definition. Clin. Nutr. 27, 793–799 (2008)PubMedCrossRef
2.
3.
Zurück zum Zitat S.D. Anker, P. Ponikowski, S. Varney, T.P. Chua, A.L. Clark, K.M. Webb-Peploe, D. Harrington, W.J. Kox, P. Poole-Wilson, A.J.S. Coats, Wasting as independent risk factor for mortality in chronic heart failure. Lancet 349, 1050–1053 (1997)PubMedCrossRef S.D. Anker, P. Ponikowski, S. Varney, T.P. Chua, A.L. Clark, K.M. Webb-Peploe, D. Harrington, W.J. Kox, P. Poole-Wilson, A.J.S. Coats, Wasting as independent risk factor for mortality in chronic heart failure. Lancet 349, 1050–1053 (1997)PubMedCrossRef
4.
Zurück zum Zitat W.E. Mitch, A.L. Goldberg, Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N. Engl. J. Med. 335, 1897–1905 (1996)PubMedCrossRef W.E. Mitch, A.L. Goldberg, Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N. Engl. J. Med. 335, 1897–1905 (1996)PubMedCrossRef
5.
Zurück zum Zitat P.O. Hasselgren, J.E. Fischer, Muscle cachexia: current concepts of intracellular mechanisms and molecular regulation. Ann. Surg. 233, 9–17 (2001)PubMedCrossRef P.O. Hasselgren, J.E. Fischer, Muscle cachexia: current concepts of intracellular mechanisms and molecular regulation. Ann. Surg. 233, 9–17 (2001)PubMedCrossRef
6.
Zurück zum Zitat H.L. Eley, S.T. Russell, M.J. Tisdale, Effect of branched-chain amino acids on muscle atrophy in cancer cachexia. Biochem. J. 407, 113–120 (2007)PubMedCrossRef H.L. Eley, S.T. Russell, M.J. Tisdale, Effect of branched-chain amino acids on muscle atrophy in cancer cachexia. Biochem. J. 407, 113–120 (2007)PubMedCrossRef
7.
Zurück zum Zitat K. Lenk, G. Schuler, V. Adams, Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J. Cachexia Sarcopenia Muscle 1, 9–21 (2010)PubMedCrossRef K. Lenk, G. Schuler, V. Adams, Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J. Cachexia Sarcopenia Muscle 1, 9–21 (2010)PubMedCrossRef
8.
Zurück zum Zitat M. Brink, A. Anwar, P. Delafontaine, Neurohormonal factors in the development of catabolic/anabolic imbalance and cachexia. Int. J. Cardiol. 85, 111–121 (2002)PubMedCrossRef M. Brink, A. Anwar, P. Delafontaine, Neurohormonal factors in the development of catabolic/anabolic imbalance and cachexia. Int. J. Cardiol. 85, 111–121 (2002)PubMedCrossRef
9.
Zurück zum Zitat P. Costelli, P. Reffo, F. Penna, R. Autelli, G. Bonelli, F.M. Baccino, Ca2+-dependent proteolysis in muscle wasting. Int. J. Biochem. Cell Biol. 37, 2134–2146 (2005)PubMedCrossRef P. Costelli, P. Reffo, F. Penna, R. Autelli, G. Bonelli, F.M. Baccino, Ca2+-dependent proteolysis in muscle wasting. Int. J. Biochem. Cell Biol. 37, 2134–2146 (2005)PubMedCrossRef
10.
Zurück zum Zitat S.H. Lecker, R.T. Jagoe, A. Gilbert, M. Gomes, V.E. Baracos, J. Bailey, S.R. Price, W.E. Mitch, A.L. Goldberg, Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. 18, 39–51 (2004)PubMedCrossRef S.H. Lecker, R.T. Jagoe, A. Gilbert, M. Gomes, V.E. Baracos, J. Bailey, S.R. Price, W.E. Mitch, A.L. Goldberg, Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. 18, 39–51 (2004)PubMedCrossRef
11.
Zurück zum Zitat M.T. Pepato, R.H. Migliorini, A.L. Goldberg, I.C. Kettelhut, Role of different proteolytic pathways in degradation of muscle protein from streptozotocin-diabetic rats. Am. J. Physiol. Endocrinol. Metab. 271, E340–E347 (1996) M.T. Pepato, R.H. Migliorini, A.L. Goldberg, I.C. Kettelhut, Role of different proteolytic pathways in degradation of muscle protein from streptozotocin-diabetic rats. Am. J. Physiol. Endocrinol. Metab. 271, E340–E347 (1996)
12.
Zurück zum Zitat T.N. Sato, Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376, 70–74 (1995)PubMedCrossRef T.N. Sato, Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376, 70–74 (1995)PubMedCrossRef
13.
Zurück zum Zitat A. Yndestad, J.K. Damas, E. Oie, T. Ueland, L. Gullestad, P. Aukrust, Role of inflammation in the progression of heart failure. Curr. Cardiol. Rep. 9, 236–241 (2007)PubMedCrossRef A. Yndestad, J.K. Damas, E. Oie, T. Ueland, L. Gullestad, P. Aukrust, Role of inflammation in the progression of heart failure. Curr. Cardiol. Rep. 9, 236–241 (2007)PubMedCrossRef
14.
Zurück zum Zitat D. Hasper, M. Hummel, F.X. Kleber, I. Reindl, H.D. Volk, Systemic inflammation in patients with heart failure. Eur. Heart J. 19, 761–765 (1998)PubMedCrossRef D. Hasper, M. Hummel, F.X. Kleber, I. Reindl, H.D. Volk, Systemic inflammation in patients with heart failure. Eur. Heart J. 19, 761–765 (1998)PubMedCrossRef
15.
Zurück zum Zitat S. Anker, A.L. Clark, M. Kemp, C. Salsbury, M.M. Teixeira, P.G. Hellewell, A.J.S. Coats, Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J. Am. Coll. Cardiol. 30, 997–1001 (1997)PubMedCrossRef S. Anker, A.L. Clark, M. Kemp, C. Salsbury, M.M. Teixeira, P.G. Hellewell, A.J.S. Coats, Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J. Am. Coll. Cardiol. 30, 997–1001 (1997)PubMedCrossRef
16.
Zurück zum Zitat M. Rauchhaus, V. Koloczek, H. Volk, M. Kemp, J. Niebauer, D.P. Francis, A.J. Coats, S.D. Anker, Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. Int. J. Cardiol. 76, 125–133 (2000)PubMedCrossRef M. Rauchhaus, V. Koloczek, H. Volk, M. Kemp, J. Niebauer, D.P. Francis, A.J. Coats, S.D. Anker, Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. Int. J. Cardiol. 76, 125–133 (2000)PubMedCrossRef
17.
Zurück zum Zitat B. Levine, J. Kalman, L. Mayer, H.M. Fillit, M.P. Packer, Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 323, 236–241 (1990)PubMedCrossRef B. Levine, J. Kalman, L. Mayer, H.M. Fillit, M.P. Packer, Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 323, 236–241 (1990)PubMedCrossRef
18.
Zurück zum Zitat M. Rauchhaus, W. Doehner, D.P. Francis, C. Davos, M. Kemp, C. Liebenthal, J. Niebauer, J. Hooper, H.D. Volk, A.J.S. Coats, S.D. Anker, Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102, 3060–3067 (2000)PubMedCrossRef M. Rauchhaus, W. Doehner, D.P. Francis, C. Davos, M. Kemp, C. Liebenthal, J. Niebauer, J. Hooper, H.D. Volk, A.J.S. Coats, S.D. Anker, Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102, 3060–3067 (2000)PubMedCrossRef
19.
Zurück zum Zitat A. Deswal, N.J. Petersen, A.M. Feldman, J.B. Young, B.G. White, D.L. Mann, Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103, 2055–2059 (2001)PubMedCrossRef A. Deswal, N.J. Petersen, A.M. Feldman, J.B. Young, B.G. White, D.L. Mann, Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103, 2055–2059 (2001)PubMedCrossRef
20.
Zurück zum Zitat C. Cappuzzello, L. Di Vito, R. Melchionna, G. Melillo, L. Silvestri, E. Cesareo, F. Crea, G. Liuzzo, A. Facchiano, M. Capogrossi, M. Napolitano, Increase of plasma IL-9 and decrease of plasma IL-5, IL-7, and IFN-gamma in patients with chronic heart failure. J. Transl. Med. 9, 28–34 (2011)PubMedCrossRef C. Cappuzzello, L. Di Vito, R. Melchionna, G. Melillo, L. Silvestri, E. Cesareo, F. Crea, G. Liuzzo, A. Facchiano, M. Capogrossi, M. Napolitano, Increase of plasma IL-9 and decrease of plasma IL-5, IL-7, and IFN-gamma in patients with chronic heart failure. J. Transl. Med. 9, 28–34 (2011)PubMedCrossRef
21.
Zurück zum Zitat M. Niethammer, M. Sieber, S. von Haehling, S.D. Anker, T. Munzel, G. Horstick, S. Genth-Zotz, Inflammatory pathways in patients with heart failure and preserved ejection fraction. Int. J. Cardiol. 129, 111–117 (2008)PubMedCrossRef M. Niethammer, M. Sieber, S. von Haehling, S.D. Anker, T. Munzel, G. Horstick, S. Genth-Zotz, Inflammatory pathways in patients with heart failure and preserved ejection fraction. Int. J. Cardiol. 129, 111–117 (2008)PubMedCrossRef
22.
Zurück zum Zitat C. Garcia-Martinez, F.J. Lopez-Soriano, J.M. Argiles, Acute treatment with tumor necrosis factor-alpha induces changes in protein metabolism in rat skeletal muscle. Mol. Cell. Biochem. 125, 11–18 (1993)PubMedCrossRef C. Garcia-Martinez, F.J. Lopez-Soriano, J.M. Argiles, Acute treatment with tumor necrosis factor-alpha induces changes in protein metabolism in rat skeletal muscle. Mol. Cell. Biochem. 125, 11–18 (1993)PubMedCrossRef
23.
Zurück zum Zitat Y.P. Li, R.J. Schwartz, I.D. Waddell, B.R. Holloway, M.B. Reid, Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-+¦B activation in response to tumor necrosis factor alpha. FASEB J. 12, 871–880 (1998)PubMed Y.P. Li, R.J. Schwartz, I.D. Waddell, B.R. Holloway, M.B. Reid, Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-+¦B activation in response to tumor necrosis factor alpha. FASEB J. 12, 871–880 (1998)PubMed
24.
25.
Zurück zum Zitat S. Acharyya, K.J. Ladner, L.L. Nelsen, J. Damrauer, P.J. Reiser, S. Swoap, D.C. Guttridge, Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest 114, 370–378 (2004)PubMed S. Acharyya, K.J. Ladner, L.L. Nelsen, J. Damrauer, P.J. Reiser, S. Swoap, D.C. Guttridge, Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest 114, 370–378 (2004)PubMed
26.
Zurück zum Zitat J. Cheng, K. Turksen, Q.C. Yu, H. Schreiber, M. Teng, E. Fuchs, Cachexia and graft-vs.-host-disease-type skin changes in keratin promoter-driven TNF alpha transgenic mice. Genes Dev. 6, 1444–1456 (1992)PubMedCrossRef J. Cheng, K. Turksen, Q.C. Yu, H. Schreiber, M. Teng, E. Fuchs, Cachexia and graft-vs.-host-disease-type skin changes in keratin promoter-driven TNF alpha transgenic mice. Genes Dev. 6, 1444–1456 (1992)PubMedCrossRef
27.
Zurück zum Zitat V. Adams, N. Mangner, A. Gasch, C. Krohne, S. Gielen, S. Hirner, H.J. Thierse, C.C. Witt, A. Linke, G. Schuler, S. Labeit, Induction of MuRF1 is essential for TNF-[alpha]-induced loss of muscle function in mice. J. Mol. Biol. 384, 48–59 (2008)PubMedCrossRef V. Adams, N. Mangner, A. Gasch, C. Krohne, S. Gielen, S. Hirner, H.J. Thierse, C.C. Witt, A. Linke, G. Schuler, S. Labeit, Induction of MuRF1 is essential for TNF-[alpha]-induced loss of muscle function in mice. J. Mol. Biol. 384, 48–59 (2008)PubMedCrossRef
28.
Zurück zum Zitat A. Oliff, D. Defeo-Jones, M. Boyer, D. Martinez, D. Kiefer, G. Vuocolo, A. Wolfe, S.H. Socher, Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 50, 555–563 (1987)PubMedCrossRef A. Oliff, D. Defeo-Jones, M. Boyer, D. Martinez, D. Kiefer, G. Vuocolo, A. Wolfe, S.H. Socher, Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 50, 555–563 (1987)PubMedCrossRef
29.
Zurück zum Zitat K.A. Baltgalvis, F.G. Berger, M.M. Pena, J.M. Davis, S.J. Muga, J.A. Carson, Interleukin-6 and cachexia in ApcMin/+ mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294, R393–R401 (2008)PubMedCrossRef K.A. Baltgalvis, F.G. Berger, M.M. Pena, J.M. Davis, S.J. Muga, J.A. Carson, Interleukin-6 and cachexia in ApcMin/+ mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294, R393–R401 (2008)PubMedCrossRef
30.
Zurück zum Zitat J. Batista, R.V.T. Santos, L.M. Cunha, K. Mattos, E.M. Oliveira, M.C.L. Seelaender, L.F.B.P. Costa Rosa, Changes in the pro-inflammatory cytokine production and peritoneal macrophage function in rats with chronic heart failure. Cytokine 34, 284–290 (2006)PubMedCrossRef J. Batista, R.V.T. Santos, L.M. Cunha, K. Mattos, E.M. Oliveira, M.C.L. Seelaender, L.F.B.P. Costa Rosa, Changes in the pro-inflammatory cytokine production and peritoneal macrophage function in rats with chronic heart failure. Cytokine 34, 284–290 (2006)PubMedCrossRef
31.
Zurück zum Zitat M.A. Panaro, N. Gagliardi, C. Saponaro, R. Calvello, V. Mitolo, A. Cianciulli, Toll-like receptor 4 mediates LPS-induced release of nitric oxide and tumor necrosis factor-alpha by embryonal cardiomyocytes: biological significance and clinical implications in human pathology. Curr. Pharm. Des. 16, 766–774 (2010)PubMedCrossRef M.A. Panaro, N. Gagliardi, C. Saponaro, R. Calvello, V. Mitolo, A. Cianciulli, Toll-like receptor 4 mediates LPS-induced release of nitric oxide and tumor necrosis factor-alpha by embryonal cardiomyocytes: biological significance and clinical implications in human pathology. Curr. Pharm. Des. 16, 766–774 (2010)PubMedCrossRef
32.
Zurück zum Zitat X.Q. Li, W. Cao, T. Li, A.G. Zeng, L.L. Hao, X.N. Zhang, Q.B. Mei, Amlodipine inhibits TNF-α production and attenuates cardiac dysfunction induced by lipopolysaccharide involving PI3K/Akt pathway. Int. Immunopharmacol. 9, 1032–1041 (2009)PubMedCrossRef X.Q. Li, W. Cao, T. Li, A.G. Zeng, L.L. Hao, X.N. Zhang, Q.B. Mei, Amlodipine inhibits TNF-α production and attenuates cardiac dysfunction induced by lipopolysaccharide involving PI3K/Akt pathway. Int. Immunopharmacol. 9, 1032–1041 (2009)PubMedCrossRef
33.
Zurück zum Zitat B.M. Meador, C.P. Krzyszton, R.W. Johnson, K.A. Huey, Effects of IL-10 and age on IL-6, IL-1beta, and TNF-α responses in mouse skeletal and cardiac muscle to an acute inflammatory insult. J. Appl. Physiol. 104, 991–997 (2008)PubMedCrossRef B.M. Meador, C.P. Krzyszton, R.W. Johnson, K.A. Huey, Effects of IL-10 and age on IL-6, IL-1beta, and TNF-α responses in mouse skeletal and cardiac muscle to an acute inflammatory insult. J. Appl. Physiol. 104, 991–997 (2008)PubMedCrossRef
34.
Zurück zum Zitat C.H. Lang, C. Silvis, N. Deshpande, G. Nystrom, R.A. Frost, Endotoxin stimulates in vivo expression of inflammatory cytokines tumor necrosis factor alpha, interleukin-1-beta, -6, and high-mobility-group protein-1 in skeletal muscle. Shock 19, 538–546 (2003)PubMedCrossRef C.H. Lang, C. Silvis, N. Deshpande, G. Nystrom, R.A. Frost, Endotoxin stimulates in vivo expression of inflammatory cytokines tumor necrosis factor alpha, interleukin-1-beta, -6, and high-mobility-group protein-1 in skeletal muscle. Shock 19, 538–546 (2003)PubMedCrossRef
35.
Zurück zum Zitat A. Sandek, M. Rauchhaus, S.D. Anker, S. von Haehling, The emerging role of the gut in chronic heart failure. Curr. Opin. Clin. Nutr. Metab. Care 11, 632–639 (2008)PubMedCrossRef A. Sandek, M. Rauchhaus, S.D. Anker, S. von Haehling, The emerging role of the gut in chronic heart failure. Curr. Opin. Clin. Nutr. Metab. Care 11, 632–639 (2008)PubMedCrossRef
36.
Zurück zum Zitat A. Sandek, J. Bauditz, A. Swidsinski, S. Buhner, J. Weber-Eibel, S. von Haehling, W. Schroedl, T. Karhausen, W. Doehner, M. Rauchhaus, P. Poole-Wilson, H.D. Volk, H. Lochs, S.D. Anker, Altered intestinal function in patients with chronic heart failure. J. Am. Coll. Cardiol. 50, 1561–1569 (2007)PubMedCrossRef A. Sandek, J. Bauditz, A. Swidsinski, S. Buhner, J. Weber-Eibel, S. von Haehling, W. Schroedl, T. Karhausen, W. Doehner, M. Rauchhaus, P. Poole-Wilson, H.D. Volk, H. Lochs, S.D. Anker, Altered intestinal function in patients with chronic heart failure. J. Am. Coll. Cardiol. 50, 1561–1569 (2007)PubMedCrossRef
37.
Zurück zum Zitat S. Genth-Zotz, S. von Haehling, A.P. Bolger, P.R. Kalra, R. Wensel, A.J.S. Coats, S.D. Anker, Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure. Am. J. Cardiol. 90, 1226–1230 (2002)PubMedCrossRef S. Genth-Zotz, S. von Haehling, A.P. Bolger, P.R. Kalra, R. Wensel, A.J.S. Coats, S.D. Anker, Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure. Am. J. Cardiol. 90, 1226–1230 (2002)PubMedCrossRef
38.
Zurück zum Zitat Y.P. Li, M.B. Reid, NF-kB mediates the protein loss induced by TNF-α in differentiated skeletal muscle. Am. J. Physiol. 279, R1165–R1170 (2000) Y.P. Li, M.B. Reid, NF-kB mediates the protein loss induced by TNF-α in differentiated skeletal muscle. Am. J. Physiol. 279, R1165–R1170 (2000)
39.
Zurück zum Zitat S.C. Kandarian, R.W. Jackman, Intracellular signaling during skeletal muscle atrophy. Muscle Nerve 33, 155–165 (2006)PubMedCrossRef S.C. Kandarian, R.W. Jackman, Intracellular signaling during skeletal muscle atrophy. Muscle Nerve 33, 155–165 (2006)PubMedCrossRef
40.
Zurück zum Zitat D. Cai, J.D. Frantz, N.E. Tawa, P.A. Melendez, B.C. Oh, H.G.W. Lidov, P.O. Hasselgren, W.R. Frontera, J. Lee, D.J. Glass, S.E. Shoelson, IKK[beta]/NF-[kappa]B activation causes severe muscle wasting in mice. Cell 119, 285–298 (2004)PubMedCrossRef D. Cai, J.D. Frantz, N.E. Tawa, P.A. Melendez, B.C. Oh, H.G.W. Lidov, P.O. Hasselgren, W.R. Frontera, J. Lee, D.J. Glass, S.E. Shoelson, IKK[beta]/NF-[kappa]B activation causes severe muscle wasting in mice. Cell 119, 285–298 (2004)PubMedCrossRef
41.
Zurück zum Zitat M. Buck, M. Chojkier, Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants. EMBO J. 15, 1753–1765 (1996)PubMed M. Buck, M. Chojkier, Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants. EMBO J. 15, 1753–1765 (1996)PubMed
42.
Zurück zum Zitat J.M. Sacheck, A. Ohtsuka, S.C. McLary, A.L. Goldberg, IGF-1 stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am. J. Physiol. Endocrinol. Metab. 287, E591–E601 (2004)PubMedCrossRef J.M. Sacheck, A. Ohtsuka, S.C. McLary, A.L. Goldberg, IGF-1 stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am. J. Physiol. Endocrinol. Metab. 287, E591–E601 (2004)PubMedCrossRef
43.
Zurück zum Zitat Y.P. Li, Y. Chen, J. John, J. Moylan, B. Jin, D.L. Mann, M.B. Reid, TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J. 19, 362–370 (2005)PubMedCrossRef Y.P. Li, Y. Chen, J. John, J. Moylan, B. Jin, D.L. Mann, M.B. Reid, TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J. 19, 362–370 (2005)PubMedCrossRef
44.
Zurück zum Zitat E. Latres, A.R. Amini, A.A. Amini, J. Griffiths, F.J. Martin, Y. Wei, H.C. Lin, G.D. Yancopoulos, D.J. Glass, Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J. Biol. Chem. 280, 2737–2744 (2005)PubMedCrossRef E. Latres, A.R. Amini, A.A. Amini, J. Griffiths, F.J. Martin, Y. Wei, H.C. Lin, G.D. Yancopoulos, D.J. Glass, Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J. Biol. Chem. 280, 2737–2744 (2005)PubMedCrossRef
45.
Zurück zum Zitat V. Adams, A. Linke, U. Wisloff, C. Doring, S. Erbs, N. Krankel, C.C. Witt, S. Labeit, U. Muller-Werdan, G. Schuler, R. Hambrecht, Myocardial expression of Murf-1 and MAFbx after induction of chronic heart failure: effect on myocardial contractility. Cardiovasc. Res. 73, 120–129 (2007)PubMedCrossRef V. Adams, A. Linke, U. Wisloff, C. Doring, S. Erbs, N. Krankel, C.C. Witt, S. Labeit, U. Muller-Werdan, G. Schuler, R. Hambrecht, Myocardial expression of Murf-1 and MAFbx after induction of chronic heart failure: effect on myocardial contractility. Cardiovasc. Res. 73, 120–129 (2007)PubMedCrossRef
46.
Zurück zum Zitat V. Adams, B. Nehrhoff, U. Späte, A. Linke, P.C. Schulze, A. Baur, S. Gielen, R. Hambrecht, G. Schuler, Induction of iNOS-expression in skeletal muscle by IL-1ß and NFκB activation: an in vitro and in vivo study. Cardiovasc. Res. 54, 95–104 (2002)PubMedCrossRef V. Adams, B. Nehrhoff, U. Späte, A. Linke, P.C. Schulze, A. Baur, S. Gielen, R. Hambrecht, G. Schuler, Induction of iNOS-expression in skeletal muscle by IL-1ß and NFκB activation: an in vitro and in vivo study. Cardiovasc. Res. 54, 95–104 (2002)PubMedCrossRef
47.
Zurück zum Zitat S. Di Marco, R. Mazroui, P. Dallaire, S. Chittur, S.A. Tenenbaum, D. Radzioch, A. Marette, I.E. Gallouzi, NF-kappa B-mediated MyoD decay during muscle wasting requires nitric oxide synthase mRNA stabilization, HuR protein, and nitric oxide release. Mol. Cell. Biol. 25, 6533–6545 (2005)PubMedCrossRef S. Di Marco, R. Mazroui, P. Dallaire, S. Chittur, S.A. Tenenbaum, D. Radzioch, A. Marette, I.E. Gallouzi, NF-kappa B-mediated MyoD decay during muscle wasting requires nitric oxide synthase mRNA stabilization, HuR protein, and nitric oxide release. Mol. Cell. Biol. 25, 6533–6545 (2005)PubMedCrossRef
48.
Zurück zum Zitat B.M. Matata, M. Galinanes, Peroxynitrite is an essential component of cytokines production mechanism in human monocytes through modulation of nuclear factor- + ¦B DNA binding activity. J. Biol. Chem. 277, 2330–2335 (2002)PubMedCrossRef B.M. Matata, M. Galinanes, Peroxynitrite is an essential component of cytokines production mechanism in human monocytes through modulation of nuclear factor- + ¦B DNA binding activity. J. Biol. Chem. 277, 2330–2335 (2002)PubMedCrossRef
49.
Zurück zum Zitat S. Gielen, V. Adams, A. Linke, S. Erbs, S. M+Âbius-Winkler, A. Schubert, G. Schuler, R. Hambrecht, Exercise training in chronic heart failure: correlation between reduced local inflammation and improved oxidative capacity in the skeletal muscle. Eur. J. Cardiovasc. Prev. Rehabil. 12, 393–400 (2005)PubMedCrossRef S. Gielen, V. Adams, A. Linke, S. Erbs, S. M+Âbius-Winkler, A. Schubert, G. Schuler, R. Hambrecht, Exercise training in chronic heart failure: correlation between reduced local inflammation and improved oxidative capacity in the skeletal muscle. Eur. J. Cardiovasc. Prev. Rehabil. 12, 393–400 (2005)PubMedCrossRef
50.
51.
Zurück zum Zitat L. Dalla-Libera, R. Sabbadini, C. Renken, B. Ravara, M. Sandri, R. Betto, A. Angelini, G. Vescovo, Apoptosis in the skeletal muscle of rats with heart failure is associated with increased serum levels of TNF-α and sphingosine. J. Mol. Cell. Cardiol. 33, 1871–1878 (2001)PubMedCrossRef L. Dalla-Libera, R. Sabbadini, C. Renken, B. Ravara, M. Sandri, R. Betto, A. Angelini, G. Vescovo, Apoptosis in the skeletal muscle of rats with heart failure is associated with increased serum levels of TNF-α and sphingosine. J. Mol. Cell. Cardiol. 33, 1871–1878 (2001)PubMedCrossRef
52.
Zurück zum Zitat G. Vescovo, L. Dalla-Libera, Skeletal muscle apoptosis in experimental heart failure: The only link between inflammation and skeletal muscle wastage? Curr. Opin. Clin. Nutr. Metab. Care 9, 416–422 (2006)PubMedCrossRef G. Vescovo, L. Dalla-Libera, Skeletal muscle apoptosis in experimental heart failure: The only link between inflammation and skeletal muscle wastage? Curr. Opin. Clin. Nutr. Metab. Care 9, 416–422 (2006)PubMedCrossRef
53.
Zurück zum Zitat V. Adams, H. Jiang, J. Yu, S. Möbius-Winkler, E. Fiehn, A. Linke, C. Weigl, G. Schuler, R. Hambrecht, Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. J. Am. Coll. Cardiol. 33, 959–965 (1999)PubMedCrossRef V. Adams, H. Jiang, J. Yu, S. Möbius-Winkler, E. Fiehn, A. Linke, C. Weigl, G. Schuler, R. Hambrecht, Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. J. Am. Coll. Cardiol. 33, 959–965 (1999)PubMedCrossRef
54.
Zurück zum Zitat G. Chen, D.V. Goeddel, TNF-R1 signaling: a beautiful pathway. Science 296, 1634–1635 (2002)PubMedCrossRef G. Chen, D.V. Goeddel, TNF-R1 signaling: a beautiful pathway. Science 296, 1634–1635 (2002)PubMedCrossRef
55.
Zurück zum Zitat V.M. Conraads, V.Y. Hoymans, T. Vermeulen, P. Beckers, N. Possemiers, M. De Maeseneer, C. Vrints, W. Martinet, Exercise capacity in chronic heart failure patients is related to active gene transcription in skeletal muscle and not apoptosis. Eur. J. Cardiovasc. Prev. Rehabil. 16, 325–332 (2009)PubMedCrossRef V.M. Conraads, V.Y. Hoymans, T. Vermeulen, P. Beckers, N. Possemiers, M. De Maeseneer, C. Vrints, W. Martinet, Exercise capacity in chronic heart failure patients is related to active gene transcription in skeletal muscle and not apoptosis. Eur. J. Cardiovasc. Prev. Rehabil. 16, 325–332 (2009)PubMedCrossRef
56.
Zurück zum Zitat S. von Haehling, S.D. Anker, Future prospects of anticytokine therapy in chronic heart failure. Expert Opin. Investig. Drugs 14, 163–176 (2005)CrossRef S. von Haehling, S.D. Anker, Future prospects of anticytokine therapy in chronic heart failure. Expert Opin. Investig. Drugs 14, 163–176 (2005)CrossRef
57.
Zurück zum Zitat D.L. Mann, J.J.V. McMurray, M. Packer, K. Swedberg, J.S. Borer, W.S. Colucci, J. Djian, H. Drexler, A. Feldman, L. Kober, H. Krum, P. Liu, M. Nieminen, L. Tavazzi, D.J. van Veldhuisen, A. Waldenstrom, M. Warren, A. Westheim, F. Zannad, T. Fleming, Targeted anticytokine therapy in patients with chronic heart failure. Circulation 109, 1594–1602 (2004)PubMedCrossRef D.L. Mann, J.J.V. McMurray, M. Packer, K. Swedberg, J.S. Borer, W.S. Colucci, J. Djian, H. Drexler, A. Feldman, L. Kober, H. Krum, P. Liu, M. Nieminen, L. Tavazzi, D.J. van Veldhuisen, A. Waldenstrom, M. Warren, A. Westheim, F. Zannad, T. Fleming, Targeted anticytokine therapy in patients with chronic heart failure. Circulation 109, 1594–1602 (2004)PubMedCrossRef
58.
Zurück zum Zitat S.D. Anker, A.J.S. Coats, How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int. J. Cardiol. 86, 123–130 (2002)PubMedCrossRef S.D. Anker, A.J.S. Coats, How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int. J. Cardiol. 86, 123–130 (2002)PubMedCrossRef
59.
Zurück zum Zitat E.S. Chung, M. Packer, K.H. Lo, A.A. Fasanmade, J.T. Willerson, ATTACH Investigators, Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α in patients with moderate-to-severe heart failure. Circulation 107, 3133–3140 (2003)PubMedCrossRef E.S. Chung, M. Packer, K.H. Lo, A.A. Fasanmade, J.T. Willerson, ATTACH Investigators, Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α in patients with moderate-to-severe heart failure. Circulation 107, 3133–3140 (2003)PubMedCrossRef
60.
Zurück zum Zitat E.P. Sampaio, E.N. Sarno, R. Galilly, G. Kaplan, Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med. 173, 699–703 (1991)PubMedCrossRef E.P. Sampaio, E.N. Sarno, R. Galilly, G. Kaplan, Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med. 173, 699–703 (1991)PubMedCrossRef
61.
Zurück zum Zitat L. Gullestad, A.G. Semb, E. Holt, R. Skardal, T. Ueland, A. Yndestad, S.S. Froland, P. Aukrust, Effect of thalidomide in patients with chronic heart failure. Am. Heart J. 144, 847–850 (2002)PubMed L. Gullestad, A.G. Semb, E. Holt, R. Skardal, T. Ueland, A. Yndestad, S.S. Froland, P. Aukrust, Effect of thalidomide in patients with chronic heart failure. Am. Heart J. 144, 847–850 (2002)PubMed
62.
Zurück zum Zitat L. Gullestad, J. Kiekshus, J.K. Damas, T. Ueland, A. Yndestad, P. Aukrust, Agents targeting inflammation in heart failure. Expert Opin. Investig. Drugs 14, 557–566 (2005)PubMedCrossRef L. Gullestad, J. Kiekshus, J.K. Damas, T. Ueland, A. Yndestad, P. Aukrust, Agents targeting inflammation in heart failure. Expert Opin. Investig. Drugs 14, 557–566 (2005)PubMedCrossRef
63.
Zurück zum Zitat I. Agoston, Z.I. Dibbs, F. Wang, G. Muller, J.B. Zeldis, D.L. Mann, B. Bozkurt, Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure. J. Card. Fail. 8, 306–314 (2002)PubMedCrossRef I. Agoston, Z.I. Dibbs, F. Wang, G. Muller, J.B. Zeldis, D.L. Mann, B. Bozkurt, Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure. J. Card. Fail. 8, 306–314 (2002)PubMedCrossRef
64.
Zurück zum Zitat L. Gullestad, T. Ueland, J.G. Fjeld, E. Holt, T. Gundersen, K. Breivik, M. Folling, A. Hodt, R. Skardal, J. Kjekshus, A. Andreassen, E. Kjekshus, R. Wergeland, A. Yndestad, S.S. Froland, A.G. Semb, P. Aukrust, Effect of thalidomide on cardiac remodeling in chronic heart failure. Circulation 112, 3408–3414 (2005)PubMedCrossRef L. Gullestad, T. Ueland, J.G. Fjeld, E. Holt, T. Gundersen, K. Breivik, M. Folling, A. Hodt, R. Skardal, J. Kjekshus, A. Andreassen, E. Kjekshus, R. Wergeland, A. Yndestad, S.S. Froland, A.G. Semb, P. Aukrust, Effect of thalidomide on cardiac remodeling in chronic heart failure. Circulation 112, 3408–3414 (2005)PubMedCrossRef
65.
Zurück zum Zitat CONSENSUS Trail Study Group, Effects of enalapril on morbidity and mortality in severe congestive heart failure. N. Engl. J. Med. 316, 1429–1431 (1987) CONSENSUS Trail Study Group, Effects of enalapril on morbidity and mortality in severe congestive heart failure. N. Engl. J. Med. 316, 1429–1431 (1987)
66.
Zurück zum Zitat SOLVD Investigators, Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325, 293–302 (1991) SOLVD Investigators, Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325, 293–302 (1991)
67.
Zurück zum Zitat M.A. Pfeffer, E. Braunwald, L.A. Moye, Effects of captopril on mortality and morbidity in patients with left ventricular dysfunktion after myocardial infarction. Result of the survival and ventricular enlargement trail. N. Engl. J. Med. 327, 669–677 (1992)PubMedCrossRef M.A. Pfeffer, E. Braunwald, L.A. Moye, Effects of captopril on mortality and morbidity in patients with left ventricular dysfunktion after myocardial infarction. Result of the survival and ventricular enlargement trail. N. Engl. J. Med. 327, 669–677 (1992)PubMedCrossRef
68.
Zurück zum Zitat Y.H. Song, Y. Li, J. Du, W.E. Mitch, N. Rosenthal, P. Delafontaine, Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest 115, 451–458 (2005)PubMed Y.H. Song, Y. Li, J. Du, W.E. Mitch, N. Rosenthal, P. Delafontaine, Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest 115, 451–458 (2005)PubMed
69.
Zurück zum Zitat B.M. Rezk, T. Yoshida, L. Semprun-Prieto, Y. Higashi, S. Sukhanov, P. Delafontaine, Angiotensin II infusion induces marked diaphragmatic skeletal muscle atrophy. PLoS ONE 7, e30276 (2012)PubMedCrossRef B.M. Rezk, T. Yoshida, L. Semprun-Prieto, Y. Higashi, S. Sukhanov, P. Delafontaine, Angiotensin II infusion induces marked diaphragmatic skeletal muscle atrophy. PLoS ONE 7, e30276 (2012)PubMedCrossRef
70.
Zurück zum Zitat S.T. Russell, P.M. Sanders, M.J. Tisdale, Angiotensin II directly inhibits protein synthesis in murine myotubes. Cancer Lett. 231, 290–294 (2006)PubMedCrossRef S.T. Russell, P.M. Sanders, M.J. Tisdale, Angiotensin II directly inhibits protein synthesis in murine myotubes. Cancer Lett. 231, 290–294 (2006)PubMedCrossRef
71.
Zurück zum Zitat S.T. Russell, S.M. Wyke, M.J. Tisdale, Mechanism of induction of muscle protein degradation by angiotensin II. Cell. Signal. 18, 1087–1096 (2006)PubMedCrossRef S.T. Russell, S.M. Wyke, M.J. Tisdale, Mechanism of induction of muscle protein degradation by angiotensin II. Cell. Signal. 18, 1087–1096 (2006)PubMedCrossRef
72.
Zurück zum Zitat T. Yoshida, L. Semprun-Prieto, S. Sukhanov, P. Delafontaine, IGF-1 prevents ANG II-induced skeletal muscle atrophy via Akt- and Foxo-dependent inhibition of the ubiquitin ligase atrogin-1 expression. Am. J. Physiol. Heart Circ. Physiol. 298, H1565–H1570 (2010)PubMedCrossRef T. Yoshida, L. Semprun-Prieto, S. Sukhanov, P. Delafontaine, IGF-1 prevents ANG II-induced skeletal muscle atrophy via Akt- and Foxo-dependent inhibition of the ubiquitin ligase atrogin-1 expression. Am. J. Physiol. Heart Circ. Physiol. 298, H1565–H1570 (2010)PubMedCrossRef
73.
Zurück zum Zitat S.D. Anker, A. Negassa, A.J. Coats, R. Afzal, P.A. Poole-Wilson, J.N. Cohn, S. Yusuf, Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 361, 1077–1083 (2003)PubMedCrossRef S.D. Anker, A. Negassa, A.J. Coats, R. Afzal, P.A. Poole-Wilson, J.N. Cohn, S. Yusuf, Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 361, 1077–1083 (2003)PubMedCrossRef
74.
Zurück zum Zitat G.D. Schellenbaum, N.L. Smith, S.R. Heckbert, T. Lumley, T.D. Rea, C.D. Furberg, M.F. Lyles, B.M. Psaty, Weight loss, muscle strength, and angiotensin-converting enzyme inhibitors in older adults with congestive heart failure or hypertension. J. Am. Geriatr. Soc. 53, 1996–2000 (2005)PubMedCrossRef G.D. Schellenbaum, N.L. Smith, S.R. Heckbert, T. Lumley, T.D. Rea, C.D. Furberg, M.F. Lyles, B.M. Psaty, Weight loss, muscle strength, and angiotensin-converting enzyme inhibitors in older adults with congestive heart failure or hypertension. J. Am. Geriatr. Soc. 53, 1996–2000 (2005)PubMedCrossRef
75.
Zurück zum Zitat M. Di Bari, L. Van De Poll-Franse, G. Onder, S.B. Kritchevsky, A. Newman, T.B. Harris, J.D. Williamson, N. Marchionni, M. Pahor, Antihypertensive medications and differences in muscle mass in older persons: the health, aging and body composition study. J. Am. Geriatr. Soc. 52, 961–966 (2004)PubMedCrossRef M. Di Bari, L. Van De Poll-Franse, G. Onder, S.B. Kritchevsky, A. Newman, T.B. Harris, J.D. Williamson, N. Marchionni, M. Pahor, Antihypertensive medications and differences in muscle mass in older persons: the health, aging and body composition study. J. Am. Geriatr. Soc. 52, 961–966 (2004)PubMedCrossRef
76.
Zurück zum Zitat E.T. Poehlman, E. Danforth, Endurance training increases metabolic rate and norepinephrine appearance rate in older individuals. Am. J. Physiol. Endocrinol. Metab. 261, E233–E239 (1991) E.T. Poehlman, E. Danforth, Endurance training increases metabolic rate and norepinephrine appearance rate in older individuals. Am. J. Physiol. Endocrinol. Metab. 261, E233–E239 (1991)
77.
Zurück zum Zitat S.D. Anker, T.P. Chua, P. Ponikowski, D. Harrington, J.W. Swan, W.J. Kox, P.A. Poole-Wilson, A.J.S. Coats, Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 96, 526–534 (1997)PubMedCrossRef S.D. Anker, T.P. Chua, P. Ponikowski, D. Harrington, J.W. Swan, W.J. Kox, P.A. Poole-Wilson, A.J.S. Coats, Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 96, 526–534 (1997)PubMedCrossRef
78.
Zurück zum Zitat T.O. Obisesan, M.J. Toth, K. Donaldson, S.S. Gottlieb, M.L. Fisher, P. Vaitekevicius, E.T. Poehlman, Energy expenditure and symptom severity in men with heart failure. Am. J. Cardiol. 77, 1250–1252 (1996)PubMedCrossRef T.O. Obisesan, M.J. Toth, K. Donaldson, S.S. Gottlieb, M.L. Fisher, P. Vaitekevicius, E.T. Poehlman, Energy expenditure and symptom severity in men with heart failure. Am. J. Cardiol. 77, 1250–1252 (1996)PubMedCrossRef
79.
Zurück zum Zitat I.S. Anand, R. Ferrari, G.S. Kalra, P.L. Wahi, P.A. Poole-Wilson, P.C. Harris, Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation 80, 299–305 (1989)PubMedCrossRef I.S. Anand, R. Ferrari, G.S. Kalra, P.L. Wahi, P.A. Poole-Wilson, P.C. Harris, Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation 80, 299–305 (1989)PubMedCrossRef
80.
81.
Zurück zum Zitat A.C. McPherron, A.M. Lawler, S.J. Lee, Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member. Nature 387, 83–90 (1997)PubMedCrossRef A.C. McPherron, A.M. Lawler, S.J. Lee, Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member. Nature 387, 83–90 (1997)PubMedCrossRef
82.
Zurück zum Zitat A.C. McPherron, S.J. Lee, Double muscling in cattle due to mutations in the myostatin gene. Proc. Natl. Acad. Sci. USA 94, 12457–12461 (1997)PubMedCrossRef A.C. McPherron, S.J. Lee, Double muscling in cattle due to mutations in the myostatin gene. Proc. Natl. Acad. Sci. USA 94, 12457–12461 (1997)PubMedCrossRef
83.
Zurück zum Zitat M. Schuelke, K.R. Wagner, L.E. Stolz, C. Hubner, T. Riebel, W. Komen, T. Braun, J.F. Tobin, S.J. Lee, Myostatin mutation associated with gross muscle hypertrophy in a child. N. Engl. J. Med. 350, 2682–2688 (2004)PubMedCrossRef M. Schuelke, K.R. Wagner, L.E. Stolz, C. Hubner, T. Riebel, W. Komen, T. Braun, J.F. Tobin, S.J. Lee, Myostatin mutation associated with gross muscle hypertrophy in a child. N. Engl. J. Med. 350, 2682–2688 (2004)PubMedCrossRef
84.
Zurück zum Zitat N.F. Gonzales-Cadavid, W.E. Taylor, K. Yaresheski, I. Sinha-Hikim, K. Ma, S. Ezzat, R. Shen, R. Lalani, S. Asa, M. Mamita, G. Nair, S. Arver, S. Bhasin, Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc. Natl. Acad. Sci. USA 95, 14938–14943 (1998)CrossRef N.F. Gonzales-Cadavid, W.E. Taylor, K. Yaresheski, I. Sinha-Hikim, K. Ma, S. Ezzat, R. Shen, R. Lalani, S. Asa, M. Mamita, G. Nair, S. Arver, S. Bhasin, Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc. Natl. Acad. Sci. USA 95, 14938–14943 (1998)CrossRef
85.
Zurück zum Zitat K.E. Yarasheski, S. Bhasin, I. Sinha-Hikim, J. Pak-Loduca, N.F. Gonzales-Cadavid, Serum myostatin-immunoreactive protein is increased in 60–92 year old women and men with muscle wasting. J. Nutr. Health Aging 6, 343–348 (2002)PubMed K.E. Yarasheski, S. Bhasin, I. Sinha-Hikim, J. Pak-Loduca, N.F. Gonzales-Cadavid, Serum myostatin-immunoreactive protein is increased in 60–92 year old women and men with muscle wasting. J. Nutr. Health Aging 6, 343–348 (2002)PubMed
86.
Zurück zum Zitat K. Lenk, R. Schur, A. Linke, S. Erbs, Y. Matsumoto, V. Adams, G. Schuler, Impact of exercise training on myostatin expression in the myocardium and skeletal muscle in a chronic heart failure model. Eur. J. Heart Fail. 11, 342–348 (2009)PubMedCrossRef K. Lenk, R. Schur, A. Linke, S. Erbs, Y. Matsumoto, V. Adams, G. Schuler, Impact of exercise training on myostatin expression in the myocardium and skeletal muscle in a chronic heart failure model. Eur. J. Heart Fail. 11, 342–348 (2009)PubMedCrossRef
87.
Zurück zum Zitat T.A. Zimmers, M.V. Davies, L.G. Koniaris, P. Haynes, A.F. Esquela, K.N. Tomkinson, A.C. McPherron, N.M. Wolfman, S.J. Lee, Induction of cachexia in mice by systemically administered myostatin. Science 296, 1486–1488 (2002)PubMedCrossRef T.A. Zimmers, M.V. Davies, L.G. Koniaris, P. Haynes, A.F. Esquela, K.N. Tomkinson, A.C. McPherron, N.M. Wolfman, S.J. Lee, Induction of cachexia in mice by systemically administered myostatin. Science 296, 1486–1488 (2002)PubMedCrossRef
88.
Zurück zum Zitat A. Rebbapragada, H. Benchabane, J.L. Wrana, A.J. Celeste, L. Attisano, Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis. Mol. Cell. Biol. 23, 7230–7242 (2003)PubMedCrossRef A. Rebbapragada, H. Benchabane, J.L. Wrana, A.J. Celeste, L. Attisano, Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis. Mol. Cell. Biol. 23, 7230–7242 (2003)PubMedCrossRef
89.
Zurück zum Zitat S. Tajbakhsh, D. Rocancourt, G. Cossu, M. Buckingham, Redefining the genetic hierarchies controlling skeletal myogenesis: Pax-3 and Myf-5 act upstream of MyoD. Cell 89, 127–138 (1997)PubMedCrossRef S. Tajbakhsh, D. Rocancourt, G. Cossu, M. Buckingham, Redefining the genetic hierarchies controlling skeletal myogenesis: Pax-3 and Myf-5 act upstream of MyoD. Cell 89, 127–138 (1997)PubMedCrossRef
90.
Zurück zum Zitat M. Maroto, R. Reshef, A.E. Münsterberg, S. Koester, M. Goulding, A.B. Lassar, Ectopic Pax-3 activates MyoD and Myf-5 expression in embryonic mesoderm and neural tissue. Cell 89, 139–148 (1997)PubMedCrossRef M. Maroto, R. Reshef, A.E. Münsterberg, S. Koester, M. Goulding, A.B. Lassar, Ectopic Pax-3 activates MyoD and Myf-5 expression in embryonic mesoderm and neural tissue. Cell 89, 139–148 (1997)PubMedCrossRef
91.
Zurück zum Zitat B. Langley, M. Thomas, A. Bishop, M. Sharma, S. Gilmour, R. Kambadur, Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. J. Biol. Chem. 277, 49831–49840 (2002)PubMedCrossRef B. Langley, M. Thomas, A. Bishop, M. Sharma, S. Gilmour, R. Kambadur, Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. J. Biol. Chem. 277, 49831–49840 (2002)PubMedCrossRef
92.
Zurück zum Zitat C. McFarlane, A. Hennebry, M. Thomas, E. Plummer, N. Ling, M. Sharma, R. Kambadur, Myostatin signals through Pax7 to regulate satellite cell self-renewal. Exp. Cell Res. 314, 317–329 (2008)PubMedCrossRef C. McFarlane, A. Hennebry, M. Thomas, E. Plummer, N. Ling, M. Sharma, R. Kambadur, Myostatin signals through Pax7 to regulate satellite cell self-renewal. Exp. Cell Res. 314, 317–329 (2008)PubMedCrossRef
93.
Zurück zum Zitat D.L. Allen, T.G. Unterman, Regulation of myostatin expression and myoblast differentiation by FoxO and SMAD transcription factors. Am. J. Physiol. Cell Physiol. 292, C188–C199 (2007)PubMedCrossRef D.L. Allen, T.G. Unterman, Regulation of myostatin expression and myoblast differentiation by FoxO and SMAD transcription factors. Am. J. Physiol. Cell Physiol. 292, C188–C199 (2007)PubMedCrossRef
94.
Zurück zum Zitat H. Amthor, G. Nicholas, I. McKinnell, C.F. Kemp, M. Sharma, R. Kambadur, K. Patel, Follistatin complexes myostatin and antagonises myostatin-mediated inhibition of myogenesis. Dev. Biol. 270, 19–30 (2004)PubMedCrossRef H. Amthor, G. Nicholas, I. McKinnell, C.F. Kemp, M. Sharma, R. Kambadur, K. Patel, Follistatin complexes myostatin and antagonises myostatin-mediated inhibition of myogenesis. Dev. Biol. 270, 19–30 (2004)PubMedCrossRef
95.
Zurück zum Zitat S.J. Lee, Y.S. Lee, T.A. Zimmers, A. Soleimani, M.M. Matzuk, K. Tsuchida, R.D. Cohn, E.R. Barton, Regulation of muscle mass by follistatin and activins. Mol. Endocrinol. 24, 1998–2008 (2010)PubMedCrossRef S.J. Lee, Y.S. Lee, T.A. Zimmers, A. Soleimani, M.M. Matzuk, K. Tsuchida, R.D. Cohn, E.R. Barton, Regulation of muscle mass by follistatin and activins. Mol. Endocrinol. 24, 1998–2008 (2010)PubMedCrossRef
96.
Zurück zum Zitat M.M. Matzuk, N. Lu, H. Vogel, K. Sellheyer, D.R. Roop, A. Bradley, Multiple defects and perinatal death in mice deficient in follistatin. Nature 374, 360–363 (1995)PubMedCrossRef M.M. Matzuk, N. Lu, H. Vogel, K. Sellheyer, D.R. Roop, A. Bradley, Multiple defects and perinatal death in mice deficient in follistatin. Nature 374, 360–363 (1995)PubMedCrossRef
97.
Zurück zum Zitat S. Bogdanovich, T.O.B. Krag, E.R. Barton, L.D. Morris, L.A. Whittemore, R.S. Ahima, T.S. Khurana, Functional improvement of dystrophic muscle by myostatin blockade. Nature 420, 418–421 (2002)PubMedCrossRef S. Bogdanovich, T.O.B. Krag, E.R. Barton, L.D. Morris, L.A. Whittemore, R.S. Ahima, T.S. Khurana, Functional improvement of dystrophic muscle by myostatin blockade. Nature 420, 418–421 (2002)PubMedCrossRef
98.
Zurück zum Zitat L.A. Whittemore, K. Song, X. Li, J. Aghajanian, M. Davies, S. Girgenrath, J.J. Hill, M. Jalenak, P. Kelley, A. Knight, R. Maylor, D. O`Hara, A. Pearson, A. Quazi, S. Ryerson, X.Y. Tan, K.N. Tomkinson, G.M. Veldman, A. Widom, J.F. Wright, S. Wudyka, L. Zhao, N.M. Wolfman, Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem. Biophys. Res. Commun. 300, 965–971 (2003)PubMedCrossRef L.A. Whittemore, K. Song, X. Li, J. Aghajanian, M. Davies, S. Girgenrath, J.J. Hill, M. Jalenak, P. Kelley, A. Knight, R. Maylor, D. O`Hara, A. Pearson, A. Quazi, S. Ryerson, X.Y. Tan, K.N. Tomkinson, G.M. Veldman, A. Widom, J.F. Wright, S. Wudyka, L. Zhao, N.M. Wolfman, Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem. Biophys. Res. Commun. 300, 965–971 (2003)PubMedCrossRef
99.
Zurück zum Zitat K.R. Wagner, J.L. Fleckenstein, A.A. Amato, R.J. Barohn, K. Bushby, D.M. Escolar, K.M. Flanigan, A. Pestronk, R. Tawil, G.I. Wolfe, M. Eagle, J.M. Florence, W.M. King, S. Pandya, V. Straub, P. Juneau, K. Meyers, C. Csimma, T. Araujo, R. Allen, S.A. Parsons, J.M. Wozney, E.R. LaVallie, J.R. Mendell, A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann. Neurol. 63, 561–571 (2008)PubMedCrossRef K.R. Wagner, J.L. Fleckenstein, A.A. Amato, R.J. Barohn, K. Bushby, D.M. Escolar, K.M. Flanigan, A. Pestronk, R. Tawil, G.I. Wolfe, M. Eagle, J.M. Florence, W.M. King, S. Pandya, V. Straub, P. Juneau, K. Meyers, C. Csimma, T. Araujo, R. Allen, S.A. Parsons, J.M. Wozney, E.R. LaVallie, J.R. Mendell, A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann. Neurol. 63, 561–571 (2008)PubMedCrossRef
100.
Zurück zum Zitat X. Zhou, J.L. Wang, J. Lu, Y. Song, K.S. Kwak, Q. Jiao, R. Rosenfeld, Q. Chen, T. Boone, W.S. Simonet, D.L. Lacey, A.L. Goldberg, H.Q. Han, Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142, 531–543 (2010)PubMedCrossRef X. Zhou, J.L. Wang, J. Lu, Y. Song, K.S. Kwak, Q. Jiao, R. Rosenfeld, Q. Chen, T. Boone, W.S. Simonet, D.L. Lacey, A.L. Goldberg, H.Q. Han, Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142, 531–543 (2010)PubMedCrossRef
101.
Zurück zum Zitat L. Zhang, V. Rajan, E. Lin, Z. Hu, H.Q. Han, X. Zhou, Y. Song, H. Min, X. Wang, J. Du, W.E. Mitch, Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J. 25, 1653–1663 (2011)PubMedCrossRef L. Zhang, V. Rajan, E. Lin, Z. Hu, H.Q. Han, X. Zhou, Y. Song, H. Min, X. Wang, J. Du, W.E. Mitch, Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J. 25, 1653–1663 (2011)PubMedCrossRef
102.
Zurück zum Zitat J.M.P. Holly, C.M. Perks, C.E.H. Stewart, Overview of insulin-like growth factor physiology. Growth Horm. IGF Res. 10, S8–S9 (2000)PubMedCrossRef J.M.P. Holly, C.M. Perks, C.E.H. Stewart, Overview of insulin-like growth factor physiology. Growth Horm. IGF Res. 10, S8–S9 (2000)PubMedCrossRef
103.
Zurück zum Zitat D.J. Glass, Molecular mechanisms modulating muscle mass. Trends Mol. Med. 9, 344–350 (2003)PubMedCrossRef D.J. Glass, Molecular mechanisms modulating muscle mass. Trends Mol. Med. 9, 344–350 (2003)PubMedCrossRef
104.
Zurück zum Zitat N.J. Szewczyk, L.A. Jacobson, Signal-transduction networks and the regulation of muscle protein degradation. Int. J. Biochem. Cell Biol. 37, 1997–2011 (2005)PubMedCrossRef N.J. Szewczyk, L.A. Jacobson, Signal-transduction networks and the regulation of muscle protein degradation. Int. J. Biochem. Cell Biol. 37, 1997–2011 (2005)PubMedCrossRef
105.
Zurück zum Zitat S. Watanabe, T. Tamura, K. Ono, H. Horiuchi, T. Kimura, T. Kita, Y. Furukawa, Insulin-like growth factor axis (insulin-like growth factor-I/insulin-like growth factor-binding protein-3) as a prognostic predictor of heart failure: association with adiponectin. Eur. J. Heart Fail. 12, 1214–1222 (2010)PubMedCrossRef S. Watanabe, T. Tamura, K. Ono, H. Horiuchi, T. Kimura, T. Kita, Y. Furukawa, Insulin-like growth factor axis (insulin-like growth factor-I/insulin-like growth factor-binding protein-3) as a prognostic predictor of heart failure: association with adiponectin. Eur. J. Heart Fail. 12, 1214–1222 (2010)PubMedCrossRef
106.
Zurück zum Zitat S.D. Lee, L.M. Chen, W.W. Kuo, W.T. Shu, W.H. Kuo, E.J. Huang, C.C. Tsai, P.C. Li, J.Y. Liu, T.H. Chen, C.Y. Huang, Serum insulin-like growth factor-axis and matrix metalloproteinases in patients with rheumatic arthritis or rheumatic heart disease. Clin. Chim. Acta 367, 62–68 (2006)PubMedCrossRef S.D. Lee, L.M. Chen, W.W. Kuo, W.T. Shu, W.H. Kuo, E.J. Huang, C.C. Tsai, P.C. Li, J.Y. Liu, T.H. Chen, C.Y. Huang, Serum insulin-like growth factor-axis and matrix metalloproteinases in patients with rheumatic arthritis or rheumatic heart disease. Clin. Chim. Acta 367, 62–68 (2006)PubMedCrossRef
107.
Zurück zum Zitat C. Rommel, S.C. Bodine, B.A. Clarke, R. Rossman, L. Nunez, T.N. Stitt, G.D. Yancopoulos, D.J. Glass, Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol. 3, 1009–1013 (2001)PubMedCrossRef C. Rommel, S.C. Bodine, B.A. Clarke, R. Rossman, L. Nunez, T.N. Stitt, G.D. Yancopoulos, D.J. Glass, Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol. 3, 1009–1013 (2001)PubMedCrossRef
108.
Zurück zum Zitat T. Matsui, T. Nagoshi, A. Rosenzweig, Akt and PI 3-kinase signaling in cardiomyocyte hypertrophy and survival. Cell Cycle 2, 20–223 (2003)CrossRef T. Matsui, T. Nagoshi, A. Rosenzweig, Akt and PI 3-kinase signaling in cardiomyocyte hypertrophy and survival. Cell Cycle 2, 20–223 (2003)CrossRef
109.
Zurück zum Zitat C. Buechler, J. Wanninger, M. Neumeier, Adiponectin receptor binding proteins—recent advances in elucidating adiponectin signalling pathways. FEBS Lett. 584, 4280–4286 (2010) C. Buechler, J. Wanninger, M. Neumeier, Adiponectin receptor binding proteins—recent advances in elucidating adiponectin signalling pathways. FEBS Lett. 584, 4280–4286 (2010)
110.
Zurück zum Zitat M. Sandri, C. Sandri, A. Gilbert, C. Skurk, E. Calabria, A. Picard, K. Walsh, S. Schiaffino, S.H. Lecker, A.L. Goldberg, FOXO transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117, 399–412 (2004)PubMedCrossRef M. Sandri, C. Sandri, A. Gilbert, C. Skurk, E. Calabria, A. Picard, K. Walsh, S. Schiaffino, S.H. Lecker, A.L. Goldberg, FOXO transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117, 399–412 (2004)PubMedCrossRef
111.
Zurück zum Zitat M. Sandri, J. Lin, C. Handschin, W. Yang, Z.P. Arany, S.H. Lecker, A.L. Goldberg, B.M. Spiegelman, PGC-1α¦ protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc. Natl. Acad. Sci. USA 103, 16260–16265 (2006)PubMedCrossRef M. Sandri, J. Lin, C. Handschin, W. Yang, Z.P. Arany, S.H. Lecker, A.L. Goldberg, B.M. Spiegelman, PGC-1α¦ protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc. Natl. Acad. Sci. USA 103, 16260–16265 (2006)PubMedCrossRef
112.
Zurück zum Zitat R. Bassel-Duby, E.N. Olson, Signaling pathways in skeletal muscle remodeling. Annu. Rev. Biochem. 75, 19–37 (2006)PubMedCrossRef R. Bassel-Duby, E.N. Olson, Signaling pathways in skeletal muscle remodeling. Annu. Rev. Biochem. 75, 19–37 (2006)PubMedCrossRef
113.
Zurück zum Zitat C.M. Liu, Z. Yang, C.W. Liu, R. Wang, P. Tien, R. Dale, L.Q. Sun, Effect of RNA oligonucleotide targeting Foxo-1 on muscle growth in normal and cancer cachexia mice. Cancer Gene Ther. 14, 945–952 (2007)PubMedCrossRef C.M. Liu, Z. Yang, C.W. Liu, R. Wang, P. Tien, R. Dale, L.Q. Sun, Effect of RNA oligonucleotide targeting Foxo-1 on muscle growth in normal and cancer cachexia mice. Cancer Gene Ther. 14, 945–952 (2007)PubMedCrossRef
114.
Zurück zum Zitat S. Genth-Zotz, R. Zotz, S. Geil, T. Voigtländer, J. Meyer, H. Darius, Recombinant growth hormone therapy in patients with ischemic cardiomyopathy: effects on hemodynamics, left ventricular function, and cardiopulmonary exercise capacity. Circulation 99, 18–21 (1999)PubMedCrossRef S. Genth-Zotz, R. Zotz, S. Geil, T. Voigtländer, J. Meyer, H. Darius, Recombinant growth hormone therapy in patients with ischemic cardiomyopathy: effects on hemodynamics, left ventricular function, and cardiopulmonary exercise capacity. Circulation 99, 18–21 (1999)PubMedCrossRef
115.
Zurück zum Zitat S. Fazio, D. Sabatini, B. Capaldo, C. Vigorito, A. Giordano, R. Guida, F. Pardo, B. Biondi, L. Sacc+á, A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N. Engl. J. Med. 334, 809–814 (1996)PubMedCrossRef S. Fazio, D. Sabatini, B. Capaldo, C. Vigorito, A. Giordano, R. Guida, F. Pardo, B. Biondi, L. Sacc+á, A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N. Engl. J. Med. 334, 809–814 (1996)PubMedCrossRef
116.
Zurück zum Zitat K.J. Osterziel, O. Strohm, J. Schuler, M. Friedrich, D. Hänlein, R. Willenbrock, S.D. Anker, P. Poole-Wilson, M.B. Ranke, R. Dietz, Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 351, 1233–1237 (1998)PubMedCrossRef K.J. Osterziel, O. Strohm, J. Schuler, M. Friedrich, D. Hänlein, R. Willenbrock, S.D. Anker, P. Poole-Wilson, M.B. Ranke, R. Dietz, Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 351, 1233–1237 (1998)PubMedCrossRef
117.
Zurück zum Zitat J. Isgaard, C.H. Bergh, K. Caidahl, M. Lomsky, A. Hjalmarson, B.A. Bengtsson, A placebo-controlled study of growth hormone in patients with congestive heart failure. Eur. Heart J. 19, 1704–1711 (1998)PubMedCrossRef J. Isgaard, C.H. Bergh, K. Caidahl, M. Lomsky, A. Hjalmarson, B.A. Bengtsson, A placebo-controlled study of growth hormone in patients with congestive heart failure. Eur. Heart J. 19, 1704–1711 (1998)PubMedCrossRef
118.
Zurück zum Zitat J. Takala, E. Ruokonen, N.R. Webster, M.S. Nielsen, D.F. Zandstra, G. Vundelinckx, C.J. Hinds, Increased mortality associated with growth hormone treatment in critically ill adults. N. Engl. J. Med. 341, 785–792 (1999)PubMedCrossRef J. Takala, E. Ruokonen, N.R. Webster, M.S. Nielsen, D.F. Zandstra, G. Vundelinckx, C.J. Hinds, Increased mortality associated with growth hormone treatment in critically ill adults. N. Engl. J. Med. 341, 785–792 (1999)PubMedCrossRef
119.
Zurück zum Zitat R.C. Cuneo, P. Wilmshurst, C. Lowy, G. Mcgauley, P.H. Sönksen, Cardiac failure responding to growth hormone. Lancet 333, 838–839 (1989)CrossRef R.C. Cuneo, P. Wilmshurst, C. Lowy, G. Mcgauley, P.H. Sönksen, Cardiac failure responding to growth hormone. Lancet 333, 838–839 (1989)CrossRef
120.
Zurück zum Zitat J.G. O′Driscoll, D.J. Green, M. Ireland, D. Kerr, R.L. Larbalestier, Treatment of end-stage cardiac failure with growth hormone. Lancet 349, 1068 (1997)PubMedCrossRef J.G. O′Driscoll, D.J. Green, M. Ireland, D. Kerr, R.L. Larbalestier, Treatment of end-stage cardiac failure with growth hormone. Lancet 349, 1068 (1997)PubMedCrossRef
121.
Zurück zum Zitat C.J. Bagatell, W.J. Bremner, Androgens in men—uses and abuses. N. Engl. J. Med. 334, 707–715 (1996)PubMedCrossRef C.J. Bagatell, W.J. Bremner, Androgens in men—uses and abuses. N. Engl. J. Med. 334, 707–715 (1996)PubMedCrossRef
122.
123.
Zurück zum Zitat H.A. Feldman, C. Longcope, C.A. Derby, C.B. Johannes, A.B. Araujo, A.D. Coviello, W.J. Bremner, J.B. McKinlay, Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J. Clin. Endocrinol. Metab. 87, 589–598 (2002)PubMedCrossRef H.A. Feldman, C. Longcope, C.A. Derby, C.B. Johannes, A.B. Araujo, A.D. Coviello, W.J. Bremner, J.B. McKinlay, Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J. Clin. Endocrinol. Metab. 87, 589–598 (2002)PubMedCrossRef
124.
Zurück zum Zitat A.B. O′Donnell, T.G. Travison, S.S. Harris, J.L. Tenover, J.B. McKinlay, Testosterone, dehydroepiandrosterone, and physical performance in older men: results from the Massachusetts male aging study. J. Clin. Endocrinol. Metab. 91, 425–431 (2006)PubMedCrossRef A.B. O′Donnell, T.G. Travison, S.S. Harris, J.L. Tenover, J.B. McKinlay, Testosterone, dehydroepiandrosterone, and physical performance in older men: results from the Massachusetts male aging study. J. Clin. Endocrinol. Metab. 91, 425–431 (2006)PubMedCrossRef
125.
Zurück zum Zitat E.A. Jankowska, B. Biel, J. Majda, A. Szklarska, M. Lopuszanska, M. Medras, S.D. Anker, W. Banasiak, P.A. Poole-Wilson, P. Ponikowski, Anabolic deficiency in men with chronic heart failure. Circulation 114, 1829–1837 (2006)PubMedCrossRef E.A. Jankowska, B. Biel, J. Majda, A. Szklarska, M. Lopuszanska, M. Medras, S.D. Anker, W. Banasiak, P.A. Poole-Wilson, P. Ponikowski, Anabolic deficiency in men with chronic heart failure. Circulation 114, 1829–1837 (2006)PubMedCrossRef
127.
Zurück zum Zitat E.A. Jankowska, G. Filippatos, B. Ponikowska, L. Borodulin-Nadzieja, S.D. Anker, W. Banasiak, P.A. Poole-Wilson, P. Ponikowski, Reduction in circulating testosterone relates to exercise capacity in men with chronic heart failure. J. Card. Fail. 15, 442–450 (2009)PubMedCrossRef E.A. Jankowska, G. Filippatos, B. Ponikowska, L. Borodulin-Nadzieja, S.D. Anker, W. Banasiak, P.A. Poole-Wilson, P. Ponikowski, Reduction in circulating testosterone relates to exercise capacity in men with chronic heart failure. J. Card. Fail. 15, 442–450 (2009)PubMedCrossRef
128.
Zurück zum Zitat G. Güder, S. Frantz, J. Bauersachs, B. Allolio, G. Ertl, C.E. Angermann, S. Störk, Low circulating androgens and mortality risk in heart failure. Heart 96, 504–509 (2010)PubMedCrossRef G. Güder, S. Frantz, J. Bauersachs, B. Allolio, G. Ertl, C.E. Angermann, S. Störk, Low circulating androgens and mortality risk in heart failure. Heart 96, 504–509 (2010)PubMedCrossRef
129.
Zurück zum Zitat E. Wehr, S. Pilz, B.O. Boehm, W. März, T. Grammer, B. Obermayer-Pietsch, Low free testosterone is associated with heart failure mortality in older men referred for coronary angiography. Eur. J. Heart Fail. 13, 482–488 (2011)PubMedCrossRef E. Wehr, S. Pilz, B.O. Boehm, W. März, T. Grammer, B. Obermayer-Pietsch, Low free testosterone is associated with heart failure mortality in older men referred for coronary angiography. Eur. J. Heart Fail. 13, 482–488 (2011)PubMedCrossRef
130.
Zurück zum Zitat G. Caminiti, M. Volterrani, F. Iellamo, G. Marazzi, R. Massaro, M. Miceli, C. Mammi, M. Piepoli, M. Fini, G.M.C. Rosano, Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure: a double-blind, placebo-controlled, randomized study. J. Am. Coll. Cardiol. 54, 919–927 (2009)PubMedCrossRef G. Caminiti, M. Volterrani, F. Iellamo, G. Marazzi, R. Massaro, M. Miceli, C. Mammi, M. Piepoli, M. Fini, G.M.C. Rosano, Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure: a double-blind, placebo-controlled, randomized study. J. Am. Coll. Cardiol. 54, 919–927 (2009)PubMedCrossRef
131.
Zurück zum Zitat M. Toma, F.A. McAlister, E.E. Coglianese, V. Vidi, S. Vasaiwala, J.A. Bakal, P.W. Armstrong, J.A. Ezekowitz, Testosterone supplementation in heart failure/clinical perspective. Circ. Heart Fail. 5, 315–321 (2012)PubMedCrossRef M. Toma, F.A. McAlister, E.E. Coglianese, V. Vidi, S. Vasaiwala, J.A. Bakal, P.W. Armstrong, J.A. Ezekowitz, Testosterone supplementation in heart failure/clinical perspective. Circ. Heart Fail. 5, 315–321 (2012)PubMedCrossRef
132.
Zurück zum Zitat S. Bhasin, T.W. Storer, M. Javanbakht, N. Berman, K.E. Yarasheski, J. Phillips, M. Dike, I. Sinha-Hikim, R. Shen, R.D. Hays, G. Beall, Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA 283, 763–770 (2000)PubMedCrossRef S. Bhasin, T.W. Storer, M. Javanbakht, N. Berman, K.E. Yarasheski, J. Phillips, M. Dike, I. Sinha-Hikim, R. Shen, R.D. Hays, G. Beall, Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA 283, 763–770 (2000)PubMedCrossRef
133.
Zurück zum Zitat Ss. Yeh, B. DeGuzman, T. Kramer, Reversal of COPD-associated weight loss using the anabolic agent oxandrolone. Chest 122, 421–428 (2002)PubMedCrossRef Ss. Yeh, B. DeGuzman, T. Kramer, Reversal of COPD-associated weight loss using the anabolic agent oxandrolone. Chest 122, 421–428 (2002)PubMedCrossRef
134.
Zurück zum Zitat E. O′Neill, J. Wilding, C. Kahn, H. Van Remmen, A. McArdle, M. Jackson, G. Close, Absence of insulin signalling in skeletal muscle is associated with reduced muscle mass and function: evidence for decreased protein synthesis and not increased degradation. AGE 32, 209–222 (2010)PubMedCrossRef E. O′Neill, J. Wilding, C. Kahn, H. Van Remmen, A. McArdle, M. Jackson, G. Close, Absence of insulin signalling in skeletal muscle is associated with reduced muscle mass and function: evidence for decreased protein synthesis and not increased degradation. AGE 32, 209–222 (2010)PubMedCrossRef
135.
Zurück zum Zitat A.A. Sayer, H.E. Syddall, E.M. Dennison, H.J. Martin, D.I.W. Phillips, C. Cooper, C.D. Byrne, Grip strength and the metabolic syndrome: findings from the Hertfordshire Cohort Study. QJM 100, 707–713 (2007)PubMedCrossRef A.A. Sayer, H.E. Syddall, E.M. Dennison, H.J. Martin, D.I.W. Phillips, C. Cooper, C.D. Byrne, Grip strength and the metabolic syndrome: findings from the Hertfordshire Cohort Study. QJM 100, 707–713 (2007)PubMedCrossRef
136.
Zurück zum Zitat S.W. Lee, G.H. Park, S.W. Lee, J.H. Song, K.C. Hong, M.J. Kim, Insulin resistance and muscle wasting in non-diabetic end-stage renal disease patients. Nephrol. Dial. Transplant. 22, 2554–2562 (2007)PubMedCrossRef S.W. Lee, G.H. Park, S.W. Lee, J.H. Song, K.C. Hong, M.J. Kim, Insulin resistance and muscle wasting in non-diabetic end-stage renal disease patients. Nephrol. Dial. Transplant. 22, 2554–2562 (2007)PubMedCrossRef
137.
Zurück zum Zitat P. Daneryd, L. Hafström, E. Svanberg, I. Karlberg, Insulin sensitivity, hormonal levels and skeletal muscle protein metabolism in tumour-bearing exercising rats. Eur. J. Cancer 31A, 97–103 (1995)PubMedCrossRef P. Daneryd, L. Hafström, E. Svanberg, I. Karlberg, Insulin sensitivity, hormonal levels and skeletal muscle protein metabolism in tumour-bearing exercising rats. Eur. J. Cancer 31A, 97–103 (1995)PubMedCrossRef
138.
Zurück zum Zitat E. Ingelsson, J. Sundström, J. Arnlöv, B. Zethelius, L. Lind, Insulin resistance and risk of congestive heart failure. JAMA 294, 334–341 (2005)PubMedCrossRef E. Ingelsson, J. Sundström, J. Arnlöv, B. Zethelius, L. Lind, Insulin resistance and risk of congestive heart failure. JAMA 294, 334–341 (2005)PubMedCrossRef
139.
Zurück zum Zitat Y. Ohta, S. Kinugawa, S. Matsushima, T. Ono, M.A. Sobirin, N. Inoue, T. Yokota, K. Hirabayashi, H. Tsutsui, Oxidative stress impairs insulin signal in skeletal muscle and causes insulin resistance in postinfarct heart failure. Am. J. Physiol. Heart Circ. Physiol. 300, H1637–H1644 (2011)PubMedCrossRef Y. Ohta, S. Kinugawa, S. Matsushima, T. Ono, M.A. Sobirin, N. Inoue, T. Yokota, K. Hirabayashi, H. Tsutsui, Oxidative stress impairs insulin signal in skeletal muscle and causes insulin resistance in postinfarct heart failure. Am. J. Physiol. Heart Circ. Physiol. 300, H1637–H1644 (2011)PubMedCrossRef
140.
Zurück zum Zitat G.A. Nader, Molecular determinants of skeletal muscle mass: getting the “AKT” together. Int. J. Biochem. Cell Biol. 37, 1985–1996 (2005)PubMedCrossRef G.A. Nader, Molecular determinants of skeletal muscle mass: getting the “AKT” together. Int. J. Biochem. Cell Biol. 37, 1985–1996 (2005)PubMedCrossRef
141.
Zurück zum Zitat C. Guillet, Y. Boirie, Insulin resistance: a contributing factor to age-related muscle mass loss. Diabetes Metab. 31, 5820–5826 (2005)CrossRef C. Guillet, Y. Boirie, Insulin resistance: a contributing factor to age-related muscle mass loss. Diabetes Metab. 31, 5820–5826 (2005)CrossRef
142.
Zurück zum Zitat K. Takaya, H. Ariyasu, N. Kanamoto, H. Iwakura, A. Yoshimoto, M. Harada, K. Mori, Y. Komatsu, T. Usui, A. Shimatsu, Y. Ogawa, K. Hosoda, T. Akamizu, M. Kojima, K. Kangawa, K. Nakao, Ghrelin strongly stimulates growth hormone release in humans. J. Clin. Endocrinol. Metab. 85, 4908–4911 (2000)PubMedCrossRef K. Takaya, H. Ariyasu, N. Kanamoto, H. Iwakura, A. Yoshimoto, M. Harada, K. Mori, Y. Komatsu, T. Usui, A. Shimatsu, Y. Ogawa, K. Hosoda, T. Akamizu, M. Kojima, K. Kangawa, K. Nakao, Ghrelin strongly stimulates growth hormone release in humans. J. Clin. Endocrinol. Metab. 85, 4908–4911 (2000)PubMedCrossRef
143.
Zurück zum Zitat E. Arvat, M. Maccario, L. Di Vito, F. Broglio, A. Benso, C. Gottero, M. Papotti, G. Muccioli, C. Dieguez, F.F. Casanueva, R. Deghenghi, F. Camanni, E. Ghigo, Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J. Clin. Endocrinol. Metab. 86, 1169–1174 (2001)PubMedCrossRef E. Arvat, M. Maccario, L. Di Vito, F. Broglio, A. Benso, C. Gottero, M. Papotti, G. Muccioli, C. Dieguez, F.F. Casanueva, R. Deghenghi, F. Camanni, E. Ghigo, Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J. Clin. Endocrinol. Metab. 86, 1169–1174 (2001)PubMedCrossRef
144.
Zurück zum Zitat D.E. Cummings, Ghrelin and the short- and long-term regulation of appetite and body weight. Physiol. Behav. 89, 71–84 (2006)PubMedCrossRef D.E. Cummings, Ghrelin and the short- and long-term regulation of appetite and body weight. Physiol. Behav. 89, 71–84 (2006)PubMedCrossRef
145.
Zurück zum Zitat C. Ledderose, S. Kreth, A. Beiras-Fernandez, Ghrelin, a novel peptide hormone in the regulation of energy balance and cardiovascular function. Recent Pat. Endocr. Metab. Immune Drug Discov. 5, 1–6 (2012)CrossRef C. Ledderose, S. Kreth, A. Beiras-Fernandez, Ghrelin, a novel peptide hormone in the regulation of energy balance and cardiovascular function. Recent Pat. Endocr. Metab. Immune Drug Discov. 5, 1–6 (2012)CrossRef
146.
Zurück zum Zitat N. Nagaya, J. Moriya, Y. Yasumura, M. Uematsu, F. Ono, W. Shimizu, K. Ueno, M. Kitakaze, K. Miyatake, K. Kangawa, Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 110, 3674–3679 (2004)PubMedCrossRef N. Nagaya, J. Moriya, Y. Yasumura, M. Uematsu, F. Ono, W. Shimizu, K. Ueno, M. Kitakaze, K. Miyatake, K. Kangawa, Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 110, 3674–3679 (2004)PubMedCrossRef
147.
Zurück zum Zitat Y.J. Akashi, J. Springer, S.D. Anker, Cachexia in chronic heart failure: prognostic implications and novel therapeutic approaches. Curr. Heart Fail. Rep. 2, 198–203 (2005)PubMedCrossRef Y.J. Akashi, J. Springer, S.D. Anker, Cachexia in chronic heart failure: prognostic implications and novel therapeutic approaches. Curr. Heart Fail. Rep. 2, 198–203 (2005)PubMedCrossRef
148.
Zurück zum Zitat S. Palus, R. Schur, Y.J. Akashi, B. Bockmeyer, R. Datta, H. Halem, J. Dong, M.D. Culler, V. Adams, S.D. Anker, J. Springer, Ghrelin and its analogues, BIM-28131 and BIM-28125, improve body weight and regulate the expression of MuRF-1 and MAFbx in a rat heart failure model. PLoS One, e26865 (2011) S. Palus, R. Schur, Y.J. Akashi, B. Bockmeyer, R. Datta, H. Halem, J. Dong, M.D. Culler, V. Adams, S.D. Anker, J. Springer, Ghrelin and its analogues, BIM-28131 and BIM-28125, improve body weight and regulate the expression of MuRF-1 and MAFbx in a rat heart failure model. PLoS One, e26865 (2011)
149.
Zurück zum Zitat Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold, J.M. Friedman, Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425–432 (1994)PubMedCrossRef Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold, J.M. Friedman, Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425–432 (1994)PubMedCrossRef
150.
Zurück zum Zitat S. Kamohara, R. Burcelin, J.L. Halaas, J.M. Friedman, M.J. Charron, Acute stimulation of glucose metabolism in mice by leptin treatment. Nature 389, 374–377 (1997)PubMedCrossRef S. Kamohara, R. Burcelin, J.L. Halaas, J.M. Friedman, M.J. Charron, Acute stimulation of glucose metabolism in mice by leptin treatment. Nature 389, 374–377 (1997)PubMedCrossRef
151.
Zurück zum Zitat S. Margetic, C. Gazzola, G.G. Pegg, R.A. Hill, Leptin: a review of its peripheral actions and interactions. Int. J. Obes. Relat. Metab. Disord. 26, 1407–1433 (2002)PubMedCrossRef S. Margetic, C. Gazzola, G.G. Pegg, R.A. Hill, Leptin: a review of its peripheral actions and interactions. Int. J. Obes. Relat. Metab. Disord. 26, 1407–1433 (2002)PubMedCrossRef
152.
Zurück zum Zitat R.S. Ahima, D.A. Antwi, Brain regulation of appetite and satiety. Endocrinol. Metab. Clin. North Am. 37, 811–823 (2008)PubMedCrossRef R.S. Ahima, D.A. Antwi, Brain regulation of appetite and satiety. Endocrinol. Metab. Clin. North Am. 37, 811–823 (2008)PubMedCrossRef
153.
Zurück zum Zitat F. Leyva, S.D. Anker, K. Egerer, J.C. Stevenson, W.J. Kox, A.J.S. Coats, Hyperleptinaemia in chronic heart failure. Eur. Heart J. 19, 1547–1551 (1998)PubMedCrossRef F. Leyva, S.D. Anker, K. Egerer, J.C. Stevenson, W.J. Kox, A.J.S. Coats, Hyperleptinaemia in chronic heart failure. Eur. Heart J. 19, 1547–1551 (1998)PubMedCrossRef
154.
Zurück zum Zitat G.S. Filippatos, K. Tsilias, K. Venetsanou, E. Karambinos, D. Manolatos, A. Kranidis, J. Antonellis, F. Kardaras, L. Anthopoulos, G. Baltopoulos, Leptin serum levels in cachectic heart failure patients. Relationship with tumor necrosis factor-alpha system. Int. J. Cardiol. 76, 117–122 (2000)PubMedCrossRef G.S. Filippatos, K. Tsilias, K. Venetsanou, E. Karambinos, D. Manolatos, A. Kranidis, J. Antonellis, F. Kardaras, L. Anthopoulos, G. Baltopoulos, Leptin serum levels in cachectic heart failure patients. Relationship with tumor necrosis factor-alpha system. Int. J. Cardiol. 76, 117–122 (2000)PubMedCrossRef
155.
Zurück zum Zitat W. Doehner, C.D. Pflaum, M. Rauchhaus, I.F. Godsland, K. Egerer, M. Cicoira, V.G. Florea, R. Sharma, A.P. Bolger, A.J. Coats, S.D. Anker, C.J. Strasburger, Leptin, insulin sensitivity and growth hormone binding protein in chronic heart failure with and without cardiac cachexia. Eur. J. Endocrinol. 145, 727–735 (2001)PubMedCrossRef W. Doehner, C.D. Pflaum, M. Rauchhaus, I.F. Godsland, K. Egerer, M. Cicoira, V.G. Florea, R. Sharma, A.P. Bolger, A.J. Coats, S.D. Anker, C.J. Strasburger, Leptin, insulin sensitivity and growth hormone binding protein in chronic heart failure with and without cardiac cachexia. Eur. J. Endocrinol. 145, 727–735 (2001)PubMedCrossRef
156.
Zurück zum Zitat P.C. Schulze, J. Kratzsch, Leptin as a new diagnostic tool in chronic heart failure. Clin. Chim. Acta 362, 1–11 (2005)PubMedCrossRef P.C. Schulze, J. Kratzsch, Leptin as a new diagnostic tool in chronic heart failure. Clin. Chim. Acta 362, 1–11 (2005)PubMedCrossRef
157.
Zurück zum Zitat P.C. Schulze, J. Kratzsch, A. Linke, N. Schoene, V. Adams, S. Gielen, S. Erbs, S. Moebius-Winkler, G. Schuler, Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure. Eur. J. Heart Fail. 5, 33–40 (2003)PubMedCrossRef P.C. Schulze, J. Kratzsch, A. Linke, N. Schoene, V. Adams, S. Gielen, S. Erbs, S. Moebius-Winkler, G. Schuler, Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure. Eur. J. Heart Fail. 5, 33–40 (2003)PubMedCrossRef
158.
Zurück zum Zitat M.W. Nickola, L.E. Wold, P.B. Colligan, G.J. Wang, W.K. Samson, J. Ren, Leptin attenuates cardiac contraction in rat ventricular myocytes: role of NO. Hypertension 36, 501–505 (2000)PubMedCrossRef M.W. Nickola, L.E. Wold, P.B. Colligan, G.J. Wang, W.K. Samson, J. Ren, Leptin attenuates cardiac contraction in rat ventricular myocytes: role of NO. Hypertension 36, 501–505 (2000)PubMedCrossRef
159.
Zurück zum Zitat K.R. McGaffin, C.S. Moravec, C.F. McTiernan, Leptin signaling in the failing and mechanically unloaded human heart/CLINICAL PERSPECTIVE. Circ. Heart Fail. 2, 676–683 (2009)PubMedCrossRef K.R. McGaffin, C.S. Moravec, C.F. McTiernan, Leptin signaling in the failing and mechanically unloaded human heart/CLINICAL PERSPECTIVE. Circ. Heart Fail. 2, 676–683 (2009)PubMedCrossRef
160.
Zurück zum Zitat M.W. Hamrick, C. Pennington, D. Newton, D. Xie, C. Isales, Leptin deficiency produces contrasting phenotypes in bones of the limb and spine. Bone 34, 376–383 (2004)PubMedCrossRef M.W. Hamrick, C. Pennington, D. Newton, D. Xie, C. Isales, Leptin deficiency produces contrasting phenotypes in bones of the limb and spine. Bone 34, 376–383 (2004)PubMedCrossRef
161.
Zurück zum Zitat S.A. Warmington, R. Tolan, S. McBennett, Functional and histological characteristics of skeletal muscle and the effects of leptin in the genetically obese (ob/ob) mouse. Int. J. Obes. Relat. Metab. Disord. 24, 1040–1050 (2000)PubMedCrossRef S.A. Warmington, R. Tolan, S. McBennett, Functional and histological characteristics of skeletal muscle and the effects of leptin in the genetically obese (ob/ob) mouse. Int. J. Obes. Relat. Metab. Disord. 24, 1040–1050 (2000)PubMedCrossRef
162.
Zurück zum Zitat M.W. Hamrick, S. Herberg, P. Arounleut, H.Z. He, A. Shiver, R.Q. Qi, L. Zhou, C.M. Isales, Q.S. Mi, The adipokine leptin increases skeletal muscle mass and significantly alters skeletal muscle miRNA expression profile in aged mice. Biochem. Biophys. Res. Commun. 400, 379–383 (2010)PubMedCrossRef M.W. Hamrick, S. Herberg, P. Arounleut, H.Z. He, A. Shiver, R.Q. Qi, L. Zhou, C.M. Isales, Q.S. Mi, The adipokine leptin increases skeletal muscle mass and significantly alters skeletal muscle miRNA expression profile in aged mice. Biochem. Biophys. Res. Commun. 400, 379–383 (2010)PubMedCrossRef
163.
Zurück zum Zitat Y.Z. Wang, Y.N. Huang, K.Y. Sun, J.H. Qi, L. Xiang, Leptin gene transfer regulates fibromuscular development and lipid deposition in muscles via SIRT1, FOXO3a and PGC-1α in mice in vivo. Int. J. Mol. Med. 28, 617–623 (2011)PubMed Y.Z. Wang, Y.N. Huang, K.Y. Sun, J.H. Qi, L. Xiang, Leptin gene transfer regulates fibromuscular development and lipid deposition in muscles via SIRT1, FOXO3a and PGC-1α in mice in vivo. Int. J. Mol. Med. 28, 617–623 (2011)PubMed
164.
Zurück zum Zitat K. Maeda, K. Okubo, I. Shimomura, K. Mizuno, Y. Matsuzawa, K. Matsubara, Analysis of an expression profile of genes in the human adipose tissue. Gene 190, 227–235 (1997)PubMedCrossRef K. Maeda, K. Okubo, I. Shimomura, K. Mizuno, Y. Matsuzawa, K. Matsubara, Analysis of an expression profile of genes in the human adipose tissue. Gene 190, 227–235 (1997)PubMedCrossRef
165.
Zurück zum Zitat Y. Okamoto, S. Kihara, N. Ouchi, M. Nishida, Y. Arita, M. Kumada, K. Ohashi, N. Sakai, I. Shimomura, H. Kobayashi, N. Terasaka, T. Inaba, T. Funahashi, Y. Matsuzawa, Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106, 2767–2770 (2002)PubMedCrossRef Y. Okamoto, S. Kihara, N. Ouchi, M. Nishida, Y. Arita, M. Kumada, K. Ohashi, N. Sakai, I. Shimomura, H. Kobayashi, N. Terasaka, T. Inaba, T. Funahashi, Y. Matsuzawa, Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106, 2767–2770 (2002)PubMedCrossRef
166.
Zurück zum Zitat C. Kobashi, M. Urakaze, M. Kishida, E. Kibayashi, H. Kobayashi, S. Kihara, T. Funahashi, M. Takata, R. Temaru, A. Sato, K. Yamazaki, N. Nakamura, M. Kobayashi, Adiponectin inhibits endothelial synthesis of interleukin-8. Circ. Res. 97, 1245–1252 (2005)PubMedCrossRef C. Kobashi, M. Urakaze, M. Kishida, E. Kibayashi, H. Kobayashi, S. Kihara, T. Funahashi, M. Takata, R. Temaru, A. Sato, K. Yamazaki, N. Nakamura, M. Kobayashi, Adiponectin inhibits endothelial synthesis of interleukin-8. Circ. Res. 97, 1245–1252 (2005)PubMedCrossRef
167.
Zurück zum Zitat W. Koenig, N. Khuseyinova, J. Baumert, C. Meisinger, H. Löwel, Serum concentrations of adiponectin and risk of type 2 Diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-Year follow-up of a large cohort from southern Germany. J. Am. Coll. Cardiol. 48, 1369–1377 (2006)PubMedCrossRef W. Koenig, N. Khuseyinova, J. Baumert, C. Meisinger, H. Löwel, Serum concentrations of adiponectin and risk of type 2 Diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-Year follow-up of a large cohort from southern Germany. J. Am. Coll. Cardiol. 48, 1369–1377 (2006)PubMedCrossRef
168.
Zurück zum Zitat J.M. Bruun, A.S. Lihn, C. Verdich, S.B. Pedersen, S. Toubro, A. Astrup, B. Richelsen, Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am. J. Physiol. Endocrinol. Metab. 285, E527–E533 (2003)PubMed J.M. Bruun, A.S. Lihn, C. Verdich, S.B. Pedersen, S. Toubro, A. Astrup, B. Richelsen, Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am. J. Physiol. Endocrinol. Metab. 285, E527–E533 (2003)PubMed
169.
Zurück zum Zitat S.T. Gulen, F. Karadag, A.B. Karul, N. Kilicarslan, E. Ceylan, N.K. Kuman, O. Cildag, Adipokines and systemic inflammation in weight-losing lung cancer patients. Lung 190, 327–332 (2012)PubMedCrossRef S.T. Gulen, F. Karadag, A.B. Karul, N. Kilicarslan, E. Ceylan, N.K. Kuman, O. Cildag, Adipokines and systemic inflammation in weight-losing lung cancer patients. Lung 190, 327–332 (2012)PubMedCrossRef
170.
Zurück zum Zitat C. Kistorp, J. Faber, S. Galatius, F. Gustafsson, J. Frystyk, A. Flyvbjerg, P. Hildebrandt, Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 112, 1756–1762 (2005)PubMedCrossRef C. Kistorp, J. Faber, S. Galatius, F. Gustafsson, J. Frystyk, A. Flyvbjerg, P. Hildebrandt, Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 112, 1756–1762 (2005)PubMedCrossRef
171.
Zurück zum Zitat J. George, S. Patal, D. Wexler, Y. Sharabi, E. Peleg, Y. Kamari, E. Grossman, D. Sheps, G. Keren, A. Roth, Circulating adiponectin concentrations in patients with congestive heart failure. Heart 92, 1420–1424 (2006)PubMedCrossRef J. George, S. Patal, D. Wexler, Y. Sharabi, E. Peleg, Y. Kamari, E. Grossman, D. Sheps, G. Keren, A. Roth, Circulating adiponectin concentrations in patients with congestive heart failure. Heart 92, 1420–1424 (2006)PubMedCrossRef
172.
Zurück zum Zitat T. Tamura, Y. Furukawa, R. Taniguchi, Y. Sato, K. Ono, H. Horiuchi, Y. Nakagawa, T. Kita, T. Kimura, Serum adiponectin level as an independent predictor of mortality in patients with congestive heart failure. Circ. J. 71, 623–630 (2007)PubMedCrossRef T. Tamura, Y. Furukawa, R. Taniguchi, Y. Sato, K. Ono, H. Horiuchi, Y. Nakagawa, T. Kita, T. Kimura, Serum adiponectin level as an independent predictor of mortality in patients with congestive heart failure. Circ. J. 71, 623–630 (2007)PubMedCrossRef
173.
Zurück zum Zitat M.B. McEntegart, B. Awede, M.C. Petrie, N. Sattar, F.G. Dunn, N.G. MacFarlane, J.J.V. McMurray, Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur. Heart J. 28, 829–835 (2007)PubMedCrossRef M.B. McEntegart, B. Awede, M.C. Petrie, N. Sattar, F.G. Dunn, N.G. MacFarlane, J.J.V. McMurray, Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur. Heart J. 28, 829–835 (2007)PubMedCrossRef
174.
Zurück zum Zitat J. Fruebis, T.S. Tsao, S. Javorschi, D. Ebbets-Reed, M.R. Erickson, F.T. Yen, B.E. Bihain, H.F. Lodish, Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl. Acad. Sci. USA 98, 2005–2010 (2001)PubMedCrossRef J. Fruebis, T.S. Tsao, S. Javorschi, D. Ebbets-Reed, M.R. Erickson, F.T. Yen, B.E. Bihain, H.F. Lodish, Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl. Acad. Sci. USA 98, 2005–2010 (2001)PubMedCrossRef
175.
Zurück zum Zitat Y. Qi, N. Takahashi, S.M. Hileman, H.R. Patel, A.H. Berg, U.B. Pajvani, P.E. Scherer, R.S. Ahima, Adiponectin acts in the brain to decease body weight. Nat. Med. 10, 524–529 (2004)PubMedCrossRef Y. Qi, N. Takahashi, S.M. Hileman, H.R. Patel, A.H. Berg, U.B. Pajvani, P.E. Scherer, R.S. Ahima, Adiponectin acts in the brain to decease body weight. Nat. Med. 10, 524–529 (2004)PubMedCrossRef
176.
Zurück zum Zitat An.M. Van Berendoncks, P. Beckers, V.Y. Hoymans, N. Possemiers, F.L. Wuyts, C.J. Vrints, V.M. Conraads, Exercise training reduces circulating adiponectin levels in patients with chronic heart failure. Clin. Sci. 118, 281–289 (2010)PubMedCrossRef An.M. Van Berendoncks, P. Beckers, V.Y. Hoymans, N. Possemiers, F.L. Wuyts, C.J. Vrints, V.M. Conraads, Exercise training reduces circulating adiponectin levels in patients with chronic heart failure. Clin. Sci. 118, 281–289 (2010)PubMedCrossRef
177.
Zurück zum Zitat S. Adamopoulos, J. Parissis, C. Kroupis, M. Georgiadis, D. Karatzas, G. Karavolias, K. Koniavitou, A.J.S. Coats, D.Th. Kremastinos, Physical training reduces peripheral markers of inflammation in patients with chronic heart failure. Eur. Heart J. 22, 791–797 (2001)PubMedCrossRef S. Adamopoulos, J. Parissis, C. Kroupis, M. Georgiadis, D. Karatzas, G. Karavolias, K. Koniavitou, A.J.S. Coats, D.Th. Kremastinos, Physical training reduces peripheral markers of inflammation in patients with chronic heart failure. Eur. Heart J. 22, 791–797 (2001)PubMedCrossRef
178.
Zurück zum Zitat N.A. Smart, A.I. Larsen, J.P. Le Maitre, A.S. Ferraz, Effect of exercise training on interleukin-6, tumour necrosis factor alpha and functional capacity in heart failure. Cardiol. Res. Pract. 2011, 532620 (2011)PubMed N.A. Smart, A.I. Larsen, J.P. Le Maitre, A.S. Ferraz, Effect of exercise training on interleukin-6, tumour necrosis factor alpha and functional capacity in heart failure. Cardiol. Res. Pract. 2011, 532620 (2011)PubMed
179.
Zurück zum Zitat S. Gielen, V. Adams, S. Möbius-Winkler, A. Linke, S. Erbs, J. Yu, W. Kempf, A. Schubert, G. Schuler, R. Hambrecht, Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure. J. Am. Coll. Cardiol. 42, 861–868 (2003)PubMedCrossRef S. Gielen, V. Adams, S. Möbius-Winkler, A. Linke, S. Erbs, J. Yu, W. Kempf, A. Schubert, G. Schuler, R. Hambrecht, Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure. J. Am. Coll. Cardiol. 42, 861–868 (2003)PubMedCrossRef
180.
Zurück zum Zitat J. Batista, J.C. Rosa, R.D. Lopes, F.S. Lira, J. Martins, A.S. Yamashita, P.C. Brum, J. Lancha, A.C. Lopes, M. Seelaender, Exercise training changes IL-10/TNF-[alpha] ratio in the skeletal muscle of post-MI rats. Cytokine 49, 102–108 (2010)PubMedCrossRef J. Batista, J.C. Rosa, R.D. Lopes, F.S. Lira, J. Martins, A.S. Yamashita, P.C. Brum, J. Lancha, A.C. Lopes, M. Seelaender, Exercise training changes IL-10/TNF-[alpha] ratio in the skeletal muscle of post-MI rats. Cytokine 49, 102–108 (2010)PubMedCrossRef
181.
Zurück zum Zitat A. Linke, V. Adams, P.C. Schulze, S. Erbs, S. Gielen, E. Fiehn, S. Möbius-Winkler, A. Schubert, G. Schuler, R. Hambrecht, Antioxidative effects of exercise training in patients with chronic heart failure. Increase in radical scavenger enzyme activity in skeletal muscle. Circulation 111, 1763–1770 (2005)PubMedCrossRef A. Linke, V. Adams, P.C. Schulze, S. Erbs, S. Gielen, E. Fiehn, S. Möbius-Winkler, A. Schubert, G. Schuler, R. Hambrecht, Antioxidative effects of exercise training in patients with chronic heart failure. Increase in radical scavenger enzyme activity in skeletal muscle. Circulation 111, 1763–1770 (2005)PubMedCrossRef
182.
Zurück zum Zitat S. Gielen, M. Sandri, I. Kozarez, J. Kratsch, D. Teupser, J. Thiery, S. Erbs, N. Mangner, K. Lenk, R. Hambrecht, G. Schuler, V. Adams, Exercise training attenuates MuRF-1 expression in the skeletal muscle of patients with chronic heart failure independent of age: the randomized leipzig exercise intervention in chronic heart failure and aging (LEICA) catabolism study. Circulation 125, 2716–2727 (2012) S. Gielen, M. Sandri, I. Kozarez, J. Kratsch, D. Teupser, J. Thiery, S. Erbs, N. Mangner, K. Lenk, R. Hambrecht, G. Schuler, V. Adams, Exercise training attenuates MuRF-1 expression in the skeletal muscle of patients with chronic heart failure independent of age: the randomized leipzig exercise intervention in chronic heart failure and aging (LEICA) catabolism study. Circulation 125, 2716–2727 (2012)
183.
Zurück zum Zitat R. Höllriegel, E.B. Beck, A. Linke, V. Adams, S. Möbius-Winkler, N. Mangner, M. Sandri, S. Gielen, M. Gutberlet, R. Hambrecht, G. Schuler, S. Erbs, Anabolic effects of exercise training in patients with advanced chronic heart failure (NYHA IIIb): impact on ubiquitin-protein ligases expression and skeletal muscle size. Int. J. Cardiol., (2012) R. Höllriegel, E.B. Beck, A. Linke, V. Adams, S. Möbius-Winkler, N. Mangner, M. Sandri, S. Gielen, M. Gutberlet, R. Hambrecht, G. Schuler, S. Erbs, Anabolic effects of exercise training in patients with advanced chronic heart failure (NYHA IIIb): impact on ubiquitin-protein ligases expression and skeletal muscle size. Int. J. Cardiol., (2012)
184.
Zurück zum Zitat S. Fujita, T. Abe, M.J. Drummond, J.G. Cadenas, H.C. Dreyer, Y. Sato, E. Volpi, B.B. Rasmussen, Blood flow restriction during low-intensity resistance exercise increases S6K1 phosphorylation and muscle protein synthesis. J. Appl. Physiol. 103, 903–910 (2007)PubMedCrossRef S. Fujita, T. Abe, M.J. Drummond, J.G. Cadenas, H.C. Dreyer, Y. Sato, E. Volpi, B.B. Rasmussen, Blood flow restriction during low-intensity resistance exercise increases S6K1 phosphorylation and muscle protein synthesis. J. Appl. Physiol. 103, 903–910 (2007)PubMedCrossRef
185.
Zurück zum Zitat K. Baar, K. Esser, Phosphorylation of p70S6k correlates with increased skeletal muscle mass following resistance exercise. Am. J. Physiol. Cell Physiol. 276, C120–C127 (1999) K. Baar, K. Esser, Phosphorylation of p70S6k correlates with increased skeletal muscle mass following resistance exercise. Am. J. Physiol. Cell Physiol. 276, C120–C127 (1999)
186.
Zurück zum Zitat R. Hambrecht, P.C. Schulze, S. Gielen, A. Linke, S. Möbius-Winkler, S. Erbs, J. Kratzsch, A. Schubert, V. Adams, G. Schuler, Effects of exercise training on insulin-like growth factor-I expression in the skeletal muscle of non-cachectic patients with chronic heart failure. Eur. J. Cardiovasc. Prev. Rehabil. 12, 401–416 (2005)PubMedCrossRef R. Hambrecht, P.C. Schulze, S. Gielen, A. Linke, S. Möbius-Winkler, S. Erbs, J. Kratzsch, A. Schubert, V. Adams, G. Schuler, Effects of exercise training on insulin-like growth factor-I expression in the skeletal muscle of non-cachectic patients with chronic heart failure. Eur. J. Cardiovasc. Prev. Rehabil. 12, 401–416 (2005)PubMedCrossRef
Metadaten
Titel
Cachexia in chronic heart failure: endocrine determinants and treatment perspectives
verfasst von
Norman Mangner
Yae Matsuo
Gerhard Schuler
Volker Adams
Publikationsdatum
01.04.2013
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2013
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-012-9767-z

Weitere Artikel der Ausgabe 2/2013

Endocrine 2/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.